Regulatory Role of Trim33 in Morphogenesis: A Paradigm for Common Human Congenital Defects by Rajderkar, Sudha
	    
 
 
 
 
 
REGULATORY ROLE OF TRIM33 IN MORPHOGENESIS:  
A PARADIGM FOR COMMON HUMAN CONGENITAL DEFECTS 
 
by  
 
Sudha Rajderkar 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy  
(Oral Health Sciences) 
in the University of Michigan 
2016 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
Professor Vesa M Kaartinen, Chair 
Assistant Professor Sundeep Kalantry 
Professor Yuji Mishina 
Professor Charlotte M Mistretta 
Assistant Professor Brian A Pierchala 
 
 
 
 
 
	   
 
 
 
 
 
 
 
 
© 
Sudha Rajderkar 
 
All Rights Reserved 
2016 
 
 
 
 
 
 
 
 
 
 
 
	   ii	  
 
 
 
ACKNOWLEDGEMENTS 
I thank all mentors, teachers and individuals who contributed to my successful 
doctoral training: 
Vesa Kaartinen, my primary mentor and research advisor, for shaping my 
scientific thinking and for encouraging bold science ideas where necessary. I 
deeply appreciate his confidence in my success as a trainee. 
My dissertation committee for their valuable contributions through the dissertation 
process:  
Sundeep Kalantry, for insightful, constructive criticism of the project, and 
mentoring. 
Yuji Mishina, for being a kind and strict teacher at the same time and his sense of 
humor. I took a liking for developmental biology as a rotation student in his lab. 
Charlotte Mistretta, for her personal commitment to my career/scientific success. 
She has also been my academic advisor and in that role, I have benefitted 
greatly from deep, inspiring conversations with her. 
Brian Pierchala, for his unbiased critique and encouragement while pursuing a 
complex research question. 
 
I thank Jan CC Hu and James Simmer for mentoring me in my very first lab 
rotation in the OHS Program. 
	   iii	  
 
 
 
I would like to appreciate all current and past members in the Kaartinen Lab for 
the lively work environment. In particular, Kenji Yumoto, for early histological data 
for the Trim33/heart development project and Penelope Thomas, for teaching 
several techniques, providing knowledgeable comments and sharing fascination 
for the thought process. 
I also acknowledge the funding sources that made my training possible: 
University of Michigan School of Dentistry Dean’s Fellowship (2010 – 2012) 
Rackham School of Graduate Studies, for catalyzing a rewarding graduate 
school experience and for several financial awards throughout my graduate 
studies.  
Society for Developmental Biology Travel Awards 
My mentor’s NIH R01DE013085 and NIH R01HL074862 funding supported my 
training and research through candidacy. 
University of Michigan, School of Dentistry and Department of Biologic and 
Materials Sciences, for excellent research, teaching and training environment.  
Elizabeth Rodriguez, for administrative help. 
Taocong Jin “Tao”, for meticulous help with qRT-PCR experimental set up. 
Kimber Converso-Baran at CVC Echocardiography Core Lab, for timely 
assistance and recording of ex utero Doppler data for mouse embryo 
experiments.  
	   iv	  
 
 
 
University of Michigan Sequencing Core, for timely execution of RNA 
Sequencing projects. 
Kenneth Weiss at UM Department for Computational Medicine and 
Bioinformatics, for helping me acquire basic skills for computing RNA 
Sequencing data. 
Kate Karfilis (Stankunas Lab, University of Oregon, Eugene) and Emily Maclary 
(Kalantry Lab, UM Department of Human Genetics), for peer learning with RNA 
Sequencing Data. 
Unit for Laboratory Animal Medicine staff, for maintaining our mouse colony.         
Renee Quinlan: for personally investing in animal welfare.  
Oral Health Sciences PhD Program, Jan CC Hu, for her guidance and support as 
program director 
Patricia Schultz, Manette London, Kimberly Smith and Sarah Ellerholz, 
Charlene Erickson, Misty Gravelin, for readily helping with administrative 
aspects, program organization in the most cheerful manner. 
OHS Buddies, students and alumni in the program, for their friendship and 
shared experiences. 
Yoshihiro Komatsu and Honghao Zhang (Mishina Lab), for scientific discussions 
and technical help. 
 
	   v	  
 
 
 
My alma mater, Government Dental College and Hospital, Mumbai (India), for a 
strong foundation in the clinical discipline as part of becoming a clinician-
scientist. University Musical Society and University of Michigan Museum of Art: 
for providing a platform for creative and intellectual upliftment. 
My family, friends and well-wishers: 
My late grandparents - N.T. and K.N Rajderkar, who continue to be my 
exemplary role models. Sunita Nasnodkar for believing in me and supporting my 
bold career decisions. Anuradha Garud, for being a loving teacher and friend; 
Yashoda Wakankar, for her infectious positive outlook; Madhav and Ramaa 
Manjrekar - without whom my transition to the US would not have been easy.  
Kaustubh Kalkundri, my significant other, for his loving support, incredible 
patience and inspiring companionship. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   vi	  
 
 
 
 
 
 
PREFACE 
 
Following is the description of the contributions to the work presented in this 
thesis: 
I (SR) wrote all chapters with editorial guidance from my mentor, Vesa Kaartinen 
(VK). VK significantly contributed to the discussion in Chapter 4. Research 
described in Chapters 4 and 5 is under preparation as manuscripts for 
publication. VK and I co-designed experiments and all research work presented 
in this thesis is original. I optimized and conducted all experiments with VK’s help 
to cover time-away; contributions by Kenji Yumoto are kindly acknowledged 
towards data in Figures 4.10, 4.11 and 4.12 (I – L). I received valuable feedback 
on experimental procedures from Sundeep Kalantry and Yuji Mishina (YM) 
through the dissertation process.  
VK specifically instructed and trained me in derivation of mouse embryonic stem 
cell (mESC) lines; I derived the Trim33FF: UbcCreERT2 mESC lines described in 
Chapters 4 and 5. I designed and generated Trim33 RNA in situ hybridization 
(ISH) probes; the T (Brachyury) ISH probe is a kind gift from YM. Sox2-Cre 
(Stock # 004783) and UbcCre-ERT2 (Stock # 007001) mice were obtained from 
Jackson Labs. Mark Lewandoski and Robert Schwartz respectively, kindly 
provided T-Cre and Nkx2_5 –Cre mice. The UM Sequencing Core prepared  
 
	   vii	  
 
 
 
cDNA libraries and conducted RNA (Illumina) Sequencing; while computation, 
bioinformatics and statistical analyses of RNA Sequencing data was done by me.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   viii	  
 
 
 
 
 
 
TABLE OF CONTENTS 
 
 
 
ACKNOWLEDGEMENTS……………………………………………………………...ii 
PREFACE………..……………………………………………………………..………vi 
LIST OF FIGURES………………………………………………………………….…xii 
LIST OF TABLES……………………………………………………………………..xv 
ABSTRACT……………………………………………………………………………xvi 
 
CHAPTER 1...…………………………………………………………………………...1 
 
Overview of TGF- β superfamily signaling 
 
The TGF-β superfamily…………………………………………………………………1 
Binding proteins and extracellular activation of TGF-β ligands………………...…..2 
Receptors and signaling mediators……………………………………………………3 
Activation of TGF-β signal……………………………………………………………...3 
Smad-dependent signaling…………………………………………………………….4 
Smad-independent signaling…………………………………………………………..7 
Regulation of TGF-β signaling…………………………………………………………7 
Inhibition of R-Smads……………………………………………………………...……8 
Modification of chromatin landscape and transcriptional control of TGF-β-
dependent genes………...……………………………………………………………...8 
 
 
 
 
	   ix	  
 
 
 
Crosstalk with other signaling pathways and regulation of TGF-β signaling: 
Smad4 and signal convergence……………………………………………………...10 
Post-translational modifications in Smad4 and regulation of Smad4 in non-
disease states………………………………………………………………………….10 
References……………………………………………………………………………..11 
 
CHAPTER 2……………………………………………………………………………15 
 
Introduction to Trim33  
 
Introduction to Trim33…………………………………………………………………15 
Trim33 orthologues……………………………………………………………………15 
Trim33 and closely related proteins………………………………………………….17 
Trim33 expression in the mouse …………………………………………………….17 
Trim33 and TGF-β signaling in development and disease………………………..18 
Trim33 in other contexts ……………………………………………………………...19 
Trim33 in embryonic stem cells/progenitor cell fate regulation …………………..20 
Trim33 and open questions pertaining to fine tuning mechanisms of TGF-β 
signaling………………………………………………………………………………...21 
References……………………………………………………………………………..21 
 
Chapter 3………………………………………………………………………………27 
 
Synopsis of experimental mouse mutants for TGF-β R -Smads and Smad4  
 
Smad2/3 and Smad4 loss-of-function defects share phenotypic similarities with 
epiblast-specific Trim33 mutants…………………………………………………….29 
References……………………………………………………………………………..30 
 
 
 
 
	   x	  
 
 
 
 
CHAPTER 4……………………………………………………………………………32 
 
Trim33 function at late gastrulation is required for normal embryogenesis: 
implications for cardiac development 
 
Abstract…………………………………………………………………………………32 
Introduction……………………………………………………………………………..33 
Experimental Procedures……………………………………………………………..36 
Results …………………………………………………………………………………44 
Discussion………………………………………………………………………………63 
References……………………………………………………………………………..69 
 
CHAPTER 5……………………………………………………………………………77 
Trim33 regulates the naïve pluripotency network in mouse embryonic stem 
cells 
Abstract…………………………………………………………………………………77 
Introduction……………………………………………………………………………..78 
Results and Discussion…………………………………………………………….…79 
Experimental Procedures………………………………………………………….….89 
References……………………………………………………………………………..92 
 
CHAPTER 6………………………………………………………………………...….96 
Summary, conclusions and prospects 
 
Trim33 in cardiac differentiation…………………………………………………...…96 
 
Trim33 in early mES cell differentiation…………………………...………………...99 
 
Conclusions…………………………………………………………………………...100 
 
Observations from the scope of in vitro and in vivo experimental methods…...100 
 
Prospects……………………………………………………………………………...101 
 
 
	   xi	  
 
 
 
 
Significance…………………………………………………………………………...102 
 
References……………………………………………………………………………103 
 
 
APPENDIX 1…………………………………………………………………..……..107 
 
Output list of differentially expressed genes in RNA-Sequencing data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   xii	  
 
 
 
 
 
LIST OF FIGURES 
 
CHAPTER 1 
Figure 1.1 Canonical, Smad-mediated TGF-β pathway…………………………….6 
 
CHAPTER 2 
Figure 2.1 Schematic of Trim33 protein domains………………………………….16 
 
CHAPTER 4 
Figure 4.1. Experimental design for derivation of Trim33 FF:UbcCreERT2 mouse ES 
cells……………………………………………………………………………………...45 
 
Figure 4.2. Optimization of conditions and time point of Trim33 deletion  
in vitro…………………………………………………………………………………...46 
 
Figure 4.3. Trim33 deficient EBs show enhanced beating clusters in 
differentiating culture…………………………………………………………………..47 
 
Figure 4.4. Differentially expressed genes in Trim33-deficient EBs at day7 in 
differentiation……………………………………………………………………….…..48 
 
Figure 4.5 qRT-PCR validation of differentially expressed genes in RNA Seq 
screen…………………………………………………………………………………...49 
 
Figure 4.6. Trim33 interacts with activated Smad2 in differentiating ES 
cells……………………………………………………………………...………………50 
 
 
	   xiii	  
 
 
 
 
Figure 4.7. Trim33-deficient EBs show reduction in baseline pSmad2 
phosphorylation and decrease in Smad4 protein levels…………………………..51 
 
Figure 4.8.Trim33 and Brachyury (T) expression in the E8.5 mouse embryo…. 53 
 
Figure 4.9. Epiblast-specific Trim33 mutants die around E13……………..……..55 
 
Figure 4.10. Cleft palate defect in epiblast-specific Trim33 mutants occurs as a 
consequence of hypoxia………………………………………………………..…….56 
 
Figure 4.11. Epiblast-specific Trim33 mutants show a modest reduction in the 
number of early and late erythroblast populations…………………………………57 
 
Figure 4.12. Epiblast-specific Trim33 mutants display severe cardiac defects…59 
 
Figure 4.13. Tbx5, Isl1, Mttp expression is down regulated in epiblast-specific 
Trim33 mutants at E8.5…………………...…………………………………………..61 
 
Figure 4.14. Lethal phenotype of epiblast-specific Trim33 mutants is partially 
rescued by Smad4 heterozygosity…………………………………………………..62 
 
Figure 4.15. Conceptual model illustrating regulation of TGF-β superfamily 
signaling by Trim33 in the precardiac mesoderm………………………………….68 
 
 
 
 
	   xiv	  
 
 
 
 
 
 
Chapter 5 
 
Figure 5.1. Trim33KO ESCs are indistinguishable from control ESCs under non-
differentiating culture conditions……………………………………………………..80 
 
Figure 5.2. Trim33KO EBs show distinct morphology and expression profile as 
compared to control and SB431542-treated EBs……………………………….….81 
 
Figure 5.3. Trim33KO EBs show increased apoptosis at day 3.5 of 
differentiation…………………………………………………………………………...84 
 
Figure 5.4. Trim33KO EBs do not accumulate DNA double strand breaks…...….85 
 
Figure 5.5. Several core pluripotency genes are upregulated in Trim33KO 
EBs……………………………………………………………………………………...87 
 
Figure 5.6. A conceptual model of regulation of pluripotency network and exit 
from pluripotency by Trim33………………………………………………………….88 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   xv	  
 
 
 
 
 
 
LIST OF TABLES 
 
Chapter 1 
 
Table 1.1 Summary of components comprising the canonical TGF-β superfamily 
pathways…………………………………………………………………………………4 
 
 
Chapter 3 
Table 3.1 Key phenotypes in experimental mouse models of Smad genes in the 
TGF-β signaling pathway……………………………………………………………..27 
 
Chapter 4 
Table 4.1 Ex utero echocardiography data in E11.5 control and epiblast-specific 
Trim33 mutants…………………………………………………………..…………….58 
 
 
 
Appendix 1 
Table A.1 Differentially expressed genes at day 7 in control and 
Trim33FxFx:UBCreERT2 (4-OHT+) embryoid bodies……………………...……......107 
 
Table A.2. Differentially expressed genes at day 2 in control and 
Trim33FxFx:UBCreERT2 (4-OHT+) embryoid bodies…………………..…...………110 
 
Table A.3. Differentially expressed genes at day 2.5 in control and 
Trim33FxFx:UBCreERT2 (4-OHT+) embryoid bodies……………………………….117 
 
 
 
 
 
	   xvi	  
 
 
 
 
ABSTRACT 
Transforming Growth Factor – beta (TGF-β) signaling plays important, pleiotropic 
roles in embryonic development as well as tissue homeostasis. TGF-β signaling 
dose is tightly regulated in a context-specific manner and even subtle 
perturbations result in a spectrum of disease phenotypes of varying severity. In 
the canonical TGF-β pathway, TGF-β signals are mediated by activated receptor-
regulated Smads (R-Smads, Smad2/3) that form a complex with Smad4 and 
participate in transcriptional regulation of TGF-β-mediated genes with sequence 
specific DNA binding factors and context-specific co-regulators. Both Smad2/3 
and Smad4 regulate signal duration and intensity differentially. This is consistent 
with the variability and spectrum of phenotypes observed upon their conditional 
deletions in mice, with Smad2/3-associated phenotypes being more severe than 
those associated with Smad4.  However, precise mechanisms that modulate the 
functional and phenotypic differences attributed to Smad2/3 and Smad4 are 
poorly understood. Tripartite motif containing (Trim) 33 - a co-regulator of both 
activated Smad2/3 and Smad4, is a candidate gene for understanding fine tuning 
mechanisms of TGF-β signaling. Here, I have investigated the role of Trim33 in 
early embryogenesis. My results show that Trim33 controls visceral endoderm 
differentiation in vitro and pre-cardiac mesoderm differentiation in vivo. Epiblast-
specific Trim33 mutants die during the second half of gestation as a result of  
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ensuing cardiac failure. My findings imply that Trim33 is required for appropriate 
early mesendoderm differentiation soon after its induction, regulates TGF-β 
superfamily signaling in a biphasic manner in the pre-cardiac mesoderm, and 
that in more committed cell lineages Trim33 is dispensable. 
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CHAPTER 1 
Overview of TGF-β superfamily signaling 
Transforming growth factor-beta (TGF-β) ligands belong to a key class of 
secreted morphogens playing important cellular roles during embryogenesis and 
organogenesis, inflammation, homeostasis and cancer. Effects of TGF-β 
signaling are context dependent, pleiotropic and depend on the strength and 
duration of exposure to the signal (Wrana, 2013). 
 
The TGF-β superfamily 
TGF-β superfamily members are widely conserved across species and comprise 
a total of over 42 members that include TGF-β, Bone Morphogenic Proteins 
(BMPs), Activin/Nodal, Growth Differentiation Factor (GDFs) and Müllerian 
Inhibiting Substance (MIS). Sequence similarity sorts TGF-β Activin/Nodal 
together in one group while BMPs/GDFs form another group. Several cell types 
through early embryonic development and adult life secrete TGF-β /BMP family 
proteins. Others that are more restrictive in expression are Anti-Müllerian 
Hormone (AMH), also called MIS, a glycoprotein hormone secreted by Sertoli 
cells while GDF8/Myostatin is expressed in myocytes in skeletal muscle. The 
scope of this thesis is limited to TGF-β /Nodal/Activin family (Weiss and Attisano, 
2013). 
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Binding proteins and extracellular activation of TGF-β ligands 
There are 3 isoforms of TGF-β ligands, namely TGF-βs 1, 2 and 3 that signal 
through type I and type II TGF-β receptors while Nodal and Activin signal via type 
I and II activin receptors (Figure 1.1) (Massague, 2012). Precursor ligands are 
processed to cleave their pro domain(s) by convertases such that receptor-
binding sites are made accessible on the ligand molecule. Prodomains are also 
thought to attribute trafficking characteristics TGF-β ligands to their appropriate 
sites before activating signaling pathways and also trafficking ligands for 
degradation, thus regulating the extent of activation of the signaling pathway.  
Once secreted in dimeric mature form with latency-associated peptide (LAP) 
complexes, TGF-β ligands eventually form complexes with large latent complex, 
the latent TGF-β binding protein (LTBP) (Munger and Sheppard, 2011; 
Robertson et al., 2015). LTBP and LAP regulate the latency of TGF-β ligands 
allowing the extra cellular microenvironment to control ligand availability to cell 
receptors (Constam, 2014; Shi and Massague, 2003). 
There is one Nodal protein-coding gene known and characterized in the mouse, 
3 in zebra fish and 5 in the xenopus whereas none have been described so far in 
drosophila and C. elegans. This plausibly reflects on the differences in functional 
requirements for Nodal as a mesendoderm inducer in different species (Pauklin 
and Vallier, 2015).  
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Receptors and signaling mediators 
TGF-β signaling occurs via transmembrane serine/threonine kinase receptors. 
There are a total of seven Type I and five Type II receptors known across the 
entire TGF-β superfamily. TGF-β specifically binds TGF-β type I (TgfβRI or Alk5) 
and TGF-β type II (TgfβRII) receptors. Activin and Nodal, both signal via one of 
the Activin type I receptors, AcvRIa (Alk2), AcvRIb (Alk4) or AcvRIc (Alk7) and 
Activin type II receptors AcvRIIa or AcvRIIb. Cripto is a co-receptor for Nodal 
signaling or AcvRs and distinguishes the signaling process involving Activin and 
Activin receptors (Massague, 1996, 1998).  
A widely expressed chondroitin and heparin sulphate protein, betaglycan, 
functions as a co-receptor for TGF-β ligands that bind TgfβRI and TgfβRII 
receptors. It is also known as the TGF-β type III receptor and binds TGF-β2, 
which has inherently low affinity binding for TgfβRII by itself. Betaglycan is a co-
modulator of MAPK signaling as part of Smad-independent TGF-β signaling 
(discussed later in this chapter) (Bilandzic and Stenvers, 2011) (Table 1.1). 
 
Activation of TGF-β Signal 
TGF-β ligand dimers linked by disulfide bonds engage cell surface receptor 
heterotetramers consisting of two appropriate Type I and two Type II receptors. 
Type I receptors have a 30 amino acid, GS region upstream of the kinase 
domain which is absent from Type II receptors. Type II receptors are 
constitutively active. Once ligand-receptor binding occurs, the type II receptor(s) 
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trans phosphorylate type I receptors. The ligand-receptor complex is then 
internalized either by clathrin-coated pits or by lipid rafts into caveolae (Shi and 
Massague, 2003).  
 
 
Category 
 
TGF-β Pathway 
 
Activin/Nodal 
Pathway 
 
BMP Pathway 
 
Ligands 
 
 
TGF-β1, β2, β3 
 
Activin A and B 
Nodal 
 
BMP2, 4, 5,6, 7 
BMP 8A, 8B, 9 , 
10 
 
Type I receptors 
 
TgfβRI 
 
AcvRIa, AcvRIb, 
AcvRIc  
 
 
AcvRl1, AcvR1 
Bmpr1a, Bmpr1b 
 
Type II receptors 
 
TgfβRII 
 
AcvRIIa or 
AcvRIIb 
 
 
Bmpr2, AcvRIIa, 
AcvRIIb 
 
Type III receptors 
 
TgfβRIII 
Cripto 
 
TgfβRIII 
Cripto 
 
 
 
 
R-Smads 
 
Smad2, 3 
 
Smad2, 3 
 
Smad1, 5, 8 
 
Co-Smad 
 
Smad4 
 
Smad4 
 
Smad4 
 
I-Smad 
 
 
Smad7 
 
Smad7 
 
Smad6, 7 
 
Table 1.1. Summary of components comprising canonical TGF-β superfamily pathways. 
Adapted and modified from (Akhurst and Hata, 2012). R-Smads = Receptor Smads, Co-Smad = 
Co-receptor Smad, I-Smad = Inhibitory Smads. 
 
Smad-dependent signaling 
Phosphorylation of the type I receptor causes conformational changes of the 
receptor complex, which in turn facilitates docking and phosphorylation of C-
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terminal serine residues in receptor-mediated Smad proteins (R-Smads). There 
are five R- Smads and the common mediator Smad4, which transduce signals 
downstream from the activated receptors to the nucleus. Smads1, 5 and 8 are 
specific to BMP while Smads2/3 are specific to the TGF-β/Nodal/Activin pathway. 
Smad4 is the only Co-Smad known in mammals whereas another less well-
characterized isoform Smad4b exists in the xenopus (Howell et al., 1999; Schiffer 
et al., 2000).  
 
Both TGF-βs and activins signal through Smad2 and Smad3 (Table 1.1) 
(Massague et al., 2005). Smad2 and Smad3 are homologous and both bind 
through an identical motif in their L3 loop to the L45 loop of the TgfβRI. 
Phosphorylated R-Smads are activated Smads. Phosphorylation enables R-
Smads to form a complex with Smad4; the complex then accumulates in the 
nucleus. This R-Smad/Smad4 heteromeric complex regulates gene-expression in 
conjunction with promoter-specific transcription factors and cofactors. R-Smad 
proteins comprise MH1 and MH2 Mad-homology domains with an intervening 
flexible linker region. The MH1 domain confers DNA binding ability while the MH2 
domain facilitates binding with protein partners aiding several functions such as 
receptor activation, cytoplasmic retention, nuclear accumulation of the Smad 
complex and binding with other transcriptional co-regulators. A summary 
schematic of the canonical TGF-β signaling pathway is depicted in (Figure 1.1). 
Smad3 binds directly to DNA via consensus GTGC motifs while Smad2 does not 
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bind DNA due to an insertion of 30 amino acids in its N-terminal MH1 domain 
(Macias et al., 2015; Massague et al., 2005).  
 
 
Figure 1.1. Canonical, Smad-mediated TGF-β pathway. Upon ligand binding and receptor 
activation, phosphorylated Smad2/3 form a complex with Smad4. This complex accumulates into 
the nucleus where it participates in transcriptional regulation of TGF-β-regulated genes along with 
sequence specific DNA binding factors and context-specific co-regulators. Adapted from 
(Massague and Gomis, 2006). 
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Smad-independent signaling 
TGF-β signaling through non-Smad mediated pathways, so called non-canonical 
TGF-β signaling is also of relevance in many biological processes,  
e.g. in epithelial-to-mesenchymal transition (EMT), cell migration and metastasis. 
Examples include but are not limited to recruitment of Par6 by TgfβRII receptors, 
resulting in recruitment of RhoA GTPase via Smurf1 and MAP kinase and PI3 
kinase pathway involving Traf6 and mTorc mediators (Shi and Massague, 2003). 
Non-canonical TGF-β signaling is outside the scope of this thesis. However, it 
must be emphasized that Smad-dependent and Smad-independent signaling 
both can converge and co-regulate transcriptional outcomes either in a 
sequential manner or simultaneously, depending on the context. A third variation 
in R-Smad- mediated signaling involves RSmads but not Smad4, such as Ikkα-
pSmad2 (Brandl et al., 2010)and Trim33-pSmad2/3 (Xi et al., 2011). In addition 
to their role in transcriptional control of TGF-β dependent genes, Smad proteins 
namely, activated Smad3 and the Smad1 are crucial components of the Drosha 
complexes involved in microRNA biogenesis (Blahna and Hata, 2012). 
 
Regulation of TGF-β signaling 
Several factors determine the intensity and duration of TGF-β signaling. 
(Reviewed by (Massague et al., 2005; Miyazono, 2000; Xu et al., 2012)). 
Ligand availability, subtype and ligand concentration determine the extra cellular 
component and onset of TGF-β signaling. Smad proteins comprise a nuclear 
localization signal and constantly shuttle between the cytoplasm and nucleus. 
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However, in an unstimulated state, binding with SARA (Smad anchor for receptor 
activation) retains the Smads in the cytoplasm. Phosphorylation of Smad2/3 
disrupts SARA-Smad association and increases their affinity for Co-Smad4 
(Macias et al., 2015). R-Smad activation by phosphorylation is reversible by the 
activity of nuclear phosphatases that target individual or monomeric R-Smads, 
not R-Smad complexes (Wrighton et al., 2009). In contrast to Smad2/3, Smad4 
has a nuclear export signal (Hill, 2009; Watanabe et al., 2000).  
 
Inhibition of R-Smads 
Smad 6 and Smad7 function to disrupt Smad-receptor as well as Smad-Smad 
interactions and are direct targets or read outs of BMP and TGF-β signaling 
respectively (Massague et al., 2005). Importantly, Smad6/7 recruit Smurf proteins 
to upstream receptor complexes and regulate their activity by facilitating 
endocytosis (Ebisawa et al., 2001; Kavsak et al., 2000). Other signaling 
pathways such as protein kinase C (phosphorylates Smad3 and interferes with 
its binding to DNA), MAPK (interferes with translocation of Smad2/3 to the 
nucleus in certain contexts) also regulate R-Smad activity (Reviewed by (Park, 
2005)). 
 
Modification of chromatin landscape and transcriptional control of TGF-β -
dependent genes 
At the DNA level, Smad complexes recruit context dependent co-activators and 
co-repressors including histone acetyl transferases (p300 and CBP) and histone 
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deacetylases that participate in transcriptional regulation (Janknecht et al., 1998; 
Pouponnot et al., 1998). In basal states, the co-repressors TGIF, Ski and SnoN 
(Ski –related novel gene) bind the MH2 domain of R-Smads and function as 
chromatin repressors (Wotton and Massague, 2001). Activated Smads reverse 
this repression by recruiting p300 and CBP (CREB –binidng protein). Along with 
co-activators, Smad complexes bind Smad binding elements (SBE) 
(characterized for TGF-β and Nodal activated Smad2/3) and Activin response 
elements (ARE), for Activin activated Smad2/3 (Dennler et al., 1998; Lau et al., 
2012). The compositions of complexes assembled at the transcriptional level 
determine whether TGF-β signaling will induce or repress transcription of TGF-β -
dependent genes. Disassembly of Smad and Smad -bound complexes at the 
DNA level is also a determinant of signal duration or termination. Cyclin-
dependent kinases 8 and 9 (CDK8 and CDK9) dynamically phosphorylate the 
linker region of Smad2/3, influencing further utilization and disposal of Smad 
proteins (Alarcon et al., 2009). In addition, YAP1 (yes associated protein 1) - a 
transcriptional regulator simultaneously primes the linker for phosphorylation by 
GSK3 (glycogen synthase kinase 3) (Attisano and Wrana, 2013). GSK3 recruits 
and in addition, primes the binding of E3 ubiquitin (Ub) protein ligases SMURF1 
(SMAD-specific E3 ubiquitin protein ligase 1) (Al-Salihi et al., 2012) or NEDD4L 
(neural precursor cell expressed developmentally downregulated protein 4-like), 
targeting Smad proteins for polyubiquitination and proteasomal degradation (Gao 
et al., 2009).   
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Cross talk with other signaling pathways and regulation of TGF-β 
signaling: Smad4 and signal convergence 
Smad4 is sequentially phosphorylated in the linker region by GSK3. Smad4 is 
then targeted for degradation in a Wnt -dependent manner in the presence of the 
E3 UB ligase β -TrCP (β -transducing repeats –containing proteins) (Wan et al., 
2004), thus having a negative regulatory effect on TGF-β signaling. GSK3 
mediated phosphorylation of Smad4 has been shown to regulate early embryo 
development in the xenopus. Thus Smad4 is at the intersection of major 
pathways that regulate development and disease (Alarcon et al., 2009; Guo and 
Wang, 2009; Massague, 2012). 
 
Post-translational modifications in Smad4 and regulation of Smad4 in non-
disease states 
Among the many post translational modifications regulating Smad4 activity 
(reviewed by (Xu, 2006)), ubiquitination is a prominent post translational 
modification of Smad4 that regulates its activity within the nucleus. SUMOylation 
(Small Ubiquitin-like Modifier) of Smad4 by SUMO1 facilitates the nuclear 
stability and nuclear retention of Smad4, thus enhancing TGF-β signaling (Lee et 
al., 2003). Jab1 and SCF E3 ubiquitin ligases signal Smad4 for proteasomal 
degradation, limiting its activity (Wan et al., 2004). In addition, Smad4 
degradation results from Smurf activity via Smad2 or Smad6/7 (Massague et al., 
2005) or by the E3 ligase CHIP (carboxy-terminus of Hsc70 interacting protein),  
which also uniquitinates Smad1 and 3 (Li et al., 2004). An important emerging 
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context in TGF-β signaling has been the discovery of monoubiquitination of 
Smad4, which does not signal it for degradation (Wang et al., 2008). Instead, 
monoubiquitination of Smad4 by Trim33 exports it into the cytoplasm where a 
putative deubiquitinating enzyme FAM/USP9x (Fat facets in mammals	  
 /ubiquitin specific peptidase 9, X-linked) releases the bound Ubiquitin and makes 
Smad4 available to oligomerize with Smad2/3, thus maintaining TGF-β signal 
strength (Dupont et al., 2009; Wrana, 2009). 
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CHAPTER 2 
Introduction to Trim33  
The Trim nuclear family of proteins is the largest subset of E3 Ubiquitin ligases 
that contain a RING domain, which is a zinc comprising protein domain, found in 
proteins involved in the ubiquitination pathway. The nomenclature Trim connotes 
the N terminal  “tripartite” motif, which is evolutionarily conserved and is a 
hallmark of all Trim proteins. Tripartite refers to 3 domains together: the RING 
domain, which is an ubiquitin (Ub) ligase, and the B1 and B2 boxes which are 
zinc binding (Borden, 2000; Meroni, 2012; Meroni and Diez-Roux, 2005; Petrera 
and Meroni, 2012; Reymond et al., 2001). Trim33, also called as transcriptional 
intermediary factor 1 gamma (Tif1γ), is one in the Trim family of over 70 proteins, 
several of which function as transcriptional co-regulators. Trim proteins play 
important roles in developmental processes, cell differentiation and cancer (Ikeda 
and Inoue, 2012; Marin, 2012; Short and Cox, 2006) 
 
Trim33 orthologues 
Trim33 was first described as Ectodermin (ecto) in the xenopus in a functional 
screen for ectoderm determinants, ecto was shown to favor neural or ectodermal 
differentiation while blocking the mesodermal inducing ability of TGF-β signaling 
(Dupont et al., 2005). Moonshine (mon), the Trim33 orthologue in zebra fish is 
required for hematopoiesis in both embryonic and adult stages (Ransom et al., 
2004). Bonus (Bon) is the Drosophila orthologue of Trim33 (Beckstead et al., 
2005).  
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The mouse Trim33 gene consists of 20 coding exons that encode an 1142-
amino-acid protein with 96% sequence similarity to its human orthologue. There 
are two Trim33 variants in the mouse with no specific functional differences 
described to date; variant 2 lacks an alternate in-frame exon in the 3' coding 
region compared to variant 1 and is shorter than isoform 1. 
http://www.ncbi.nlm.nih.gov/protein/NP_001073299.1   
Apart from the Trim (RING and B1, B2 boxes) domain, which is common to all 
known Trim proteins, Trim33 comprises two C-terminal domains, the Plant 
Homeo Domain (PHD) and Bromo domain that engage histone modifications. 
PHD domains bind trimethylated lysines while Bromo domains bind acetylated 
lysines in histones (Gozani et al., 2003; Zeng and Zhou, 2002). Additionally, 
Trim33 proteins have a Smad binding region and a coiled- coiled domain (Yan et 
al., 2004). Figure 2.1 shows a schematic of Trim33 protein domains. 
 
Figure 2.1. Schematic of Trim33 protein domains. The C-terminal TRIM domain itself 
comprises the RING, B1 and B2 boxes, which function as an E3 ubiquitin ligase, an intervening 
consensus Smad binding region has been described along with PHD and Bromo domains that 
function in chromatin binding and interactions with modified histone proteins. Exons 1- 20 are 
corresponding Trim33 exons. 
E3 ubiquitin ligase  
Smad 
binding 
Chromatin  
binding 
TRIM domain =  
RING + B1, B2 Boxes 
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Trim33 and closely related proteins 
Trim33 forms oligomers with Trim24 and Trim28 and the three proteins share 
approximately 40% sequence identity with each other (Yan et al., 2004). Both 
Trim24 and Trim28 have a PXVXL domain that mediates binding with 
heterochromatin family of proteins such as HP1 (Herquel et al., 2011). Trim33 by 
itself has been shown to function as a multivalent chromatin-binding module via 
its PHD and Bromo domains that binds specific histone H3 tails (Massague and 
Xi, 2012). It is noteworthy that given the similarity in sequence and protein 
domains, Trim33 is reportedly the only protein known Trim family member to date 
to bind Smad proteins, Smad2/3 and Smad4 (Agricola et al., 2011; Morikawa et 
al., 2013; Xi et al., 2011). 
 
Trim33 expression in the mouse 
Trim33 is ubiquitously expressed until embryonic day 10 in the mouse and 
comparatively highly expressed in the brain and spinal cord epithelium in later 
embryonic stages (Xi et al., 2011; Yan et al., 2004). Developing sensory epithelia 
such as the oro-nasal epithelia and developing organs such as the thymus, lung, 
stomach, intestine, liver, and kidney cortex show prominent expression in in situ 
hybridization assays. Northern Blot analyses at postnatal day 10 in the mouse 
(P10) show expression in the heart, brain, spleen, lung, liver, kidney and testis, 
with barely detectable expression in skeletal muscle (Yan et al., 2004). 
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Trim33 and TGF-β signaling in development and disease  
The role of Trim33 in development was first elucidated in the xenopus where 
Trim33 was discovered in a screen of ectoderm determinants and was shown to 
control early germ cell specification (Dupont et al., 2005). Later in the mouse, 
Trim33 was shown to negatively regulate Smad4 in early patterning and Trim33 
mutants die during gastrulation or early somitogenesis (Kim and Kaartinen, 2008; 
Morsut et al., 2010). Thus, in different contexts, Trim33 was consistently shown 
to regulate TGF-β signaling. In part, the negative regulation of TGF-β signaling 
by Trim33 is attributed to monoubiquitination of Smad4 by the RING domain, 
which in turn affects Smad4 residence time within the nucleus (Agricola et al., 
2011; Dupont et al., 2012). 
Several studies have indicated the role of Trim33 in hematopoietic cells. 
Trim33 is shown to be critical for hematopoietic cell fate in development as well 
as adult hematopoiesis and ageing of hematopoietic cells (Kusy et al., 2011; 
Kusy and Romeo, 2011; Ransom et al., 2004). In early cell fate determination, 
Trim33 regulates the differentiation response in hematopoietic progenitor cells in 
a Smad4 -independent manner (He et al., 2006). Aligned with its role in 
hematopoiesis, Trim33 has a tumor suppressor role in chronic myelomonocytic 
leukemia (Aucagne et al., 2011a; Aucagne et al., 2011b).  
 Trim33 and Smad4 have redundant functions in regulating neural cell 
fates in the developing cortex (Falk et al., 2014) and share the redundancy with 
Transforming growth factor-β activated kinase 1 (Tak1), a key transducer of 
Smad -independent signaling, in palatal fusion (Lane et al., 2015). In the context 
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of mammary epithelial cells, however, Trim33 inhibits Smad4 and is required for 
their terminal differentiation and lactation (Hesling et al., 2013), also effecting 
antagonistic responses to Smad4 mediated epithelial –to -mesenchymal 
transformation (EMT) (Hesling et al., 2011). 	  
 
Trim33 in other contexts 
Trim33 is recruited to DNA damage sites in a Poly ADP Ribose Polymerase 
(PARP) -dependent manner and participates in regulating the DNA damage 
response by limiting the activity of “Amplified in Liver Cancer” 1 (ALC1), a 
chromatin remodeling enzyme; cells lacking Trim33 have higher sensitivity for 
DNA damage (Kulkarni et al., 2013). This is consistent with the function of 
Trim33 as a tumor suppressor in cancer cells (Hatakeyama, 2011), where loss of 
Trim33 results in accumulation of chromosomal defects (Pommier et al., 2015) 
and its function as a component of APC/C-mitotic checkpoint complex (Sedgwick 
et al., 2013). Others have shown that the Trim33 function as a tumor suppressor 
is due to its role in degrading nuclear beta catenin (Xue et al., 2015). Apart from 
experimental data in mouse models, data from humans are consistent with the 
tumor suppressor role of Trim33 (Aucagne et al., 2011a; Jain et al., 2011; 
Natrajan et al., 2007; Vincent et al., 2009). Additionally, autoantibodies to Trim33 
have been reported in cases of dermatomyositis (Fiorentino et al., 2015; 
Mohassel et al., 2015; Valenzuela et al., 2014). In clinical specimens from clear 
cell renal cell carcinoma (ccRCC), a histological subtype of RCC, miR-629 has 
been shown to regulate TGF-β/Smad signaling in a Trim33 -dependent manner. 
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Specifically, miR-629 directly and negatively regulates Trim33 expression 
resulting in inhibition of the TGF-β pathway. Pathological grades and stages of 
ccRCC specimens show down regulation of Trim33, consistent with its postulated 
tumor suppressor role (Jingushi et al., 2015).  
. 
Trim33 in embryonic stem cells/progenitor cell fate regulation 
In poised master regulators of differentiation in mES cells, Trim33 utilizes the 
dual histone mark H3K9me3K18ac as a differentiation switch. Upon Nodal 
stimulation, Trim33 -Smad2/3 complexes are formed simultaneous to Smad2/3 
and Smad4 complexes. The association of Trim33 - Smad2/3 and 
H3K9me3K18ac displaces Hetero Chromatin Protein 1 gamma (HP1γ), a 
chromatin repressor and allows Smad2/3 - Smad4 complexes to access Nodal 
responsive elements, which in turn facilitates RNA Polymerase II (PolII) 
recruitment allowing Gsc and Mixl1 transcription (Massague and Xi, 2012; Xi et 
al., 2011). Trim33 functions as a cell fate regulator in erythroid precursor cells by 
functioning as an elongation factor and by countering PolII pausing (Bai et al., 
2010). Trim33 regulates the balance of cell fate choice of hematopoietic stem 
cells between lymphoid and myeloid lineages in a TGF-β signaling dependent 
manner (Quere et al., 2014). 
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Trim33 and open questions pertaining to fine tuning mechanisms of  
TGF-β signaling 
In summary, in the context of development and stem cell/progenitor cell 
differentiation, Trim33 binds phosphorylated Smad2/3 (pSmad2/3) and regulates 
TGF-β signaling in a Smad4-dependent or Smad4 -independent manner. The 
question of Smad4 dependency here is not limited to the preferential binding of 
Trim33 with pSmad2/3 alone but also affected by regulation of residence time of 
Smad4 within the nucleus due to monoubiquitination by Trim33 (Agricola et al., 
2011; Wrana, 2009). Whether Smad4 -dependent or not, an additional aspect 
pertinent to the understanding of context-dependent role of Trim33 is the function 
of Trim33 - pSmad2/3 complex as a chromatin reader and poised genes that 
regulate lineage fates (Xi et al., 2011). Thus, given its versatility of function, 
Trim33 is a candidate co-regulator of TGF-β signaling in contexts where 
Smad2/3 loss of function phenotypes cannot be reconciled with Smad4 loss of 
function phenotypes (Akhurst and Padgett, 2015).  Moreover, it is imperative to 
examine the function of Trim33 in contexts where the dose of TGF-β signaling is 
tightly and dynamically regulated such that subtle perturbations in dosage result 
in abnormal outcomes of varying severity.  
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CHAPTER 3 
Synopsis of experimental mouse mutants for TGF-β R-Smads and Smad4 
As described in Chapter2, Smad2/3 and Smad4 are the main transducers of the 
activated, canonical TGF-β, Nodal/Activin pathway. Both Smad2/3 and Smad4 
regulate signal duration and intensity differentially. However, precise 
mechanisms that modulate the functional and phenotypic differences attributed to 
Smad2/3 and Smad4 are poorly understood. With respect to this work 
investigating the role Trim33 - a co-regulator of both activated Smad2/3 and 
Smad4 in embryogenesis, it is important to review the relevant phenotypes 
pertaining to experimental mouse mutants for Smad2/3 and Smad4. Table 3.1 
summarizes key phenotypes in experimental mouse models pertaining to Smad 
genes involved in the TGF-β pathway. 
 
 
Genetic 
alteration 
 
 
Experimental 
condition 
 
Phenotype 
 
Reference(s) 
 
Smad -/- 
 
Germline 
deletion 
 
Lack of mesoderm 
induction. Embryonic 
lethal between E7.5 – 
E8.5 
 
 
(Nomura and 
Li, 1998; 
Waldrip et al., 
1998; 
Weinstein et 
al., 1998) 
 
 
Smad2 -/+ 
 
Germline 
deletion 
 
One fifth of the mice 
show gastrulation 
defects, craniofacial 
abnormalities, cyclopia 
 
 
(Nomura and 
Li, 1998; 
Weinstein et 
al., 1998) 
 
Smad2 -/- 
 
Smad2-/- ES 
 
Embryonic lethal at 
 
(Heyer et al., 
	   28	  
cells in tetraploid 
complementation 
with wild type 
embryos 
 
E10.5 1999) 
 
Smad3 -/- 
 
 
Germline 
deletion 
 
Colorectal carcinomas at 
4-6 months and chronic 
infections due to lack of 
immune response 
 
 
(Zhu et al., 
1998) 
 
Smad3 -/+ 
 
Germline  
deletion 
 
 
No obvious phenotype 
 
(Zhu et al., 
1998) 
 
Smad4 -/- 
 
Germline 
deletion 
 
 
Lack of distinct 
delineation of embryonic 
and extra-embryonic 
compartments, lack of 
the mesoderm, 
abnormal development 
of visceral endoderm. 
Embryonic lethal 
between E6.5 – E8.5. 
 
 
(Sirard et al., 
1998; Yang et 
al., 1998) 
 
Smad4 -/+ 
 
Germline 
deletion 
 
 
Gastric and deudenal 
polyps > 1 year 
 
 
(Takaku et al., 
1999) 
 
Smad2 -/- 
Smad3 -/- 
 
Germline 
deletion 
 
 
Failure to gastrulate 
 
 
(Dunn et al., 
2004) 
 
Smad2 -/+ 
Smad3 -/+ 
 
Germline 
deletion 
 
 
Midline defects, defects 
in cardiac looping 
 
 
(Liu et al., 
2004) 
 
Smad2 -/- 
 
Epiblast-specific 
deletion 
 
Defects in precursors of 
the anterior definitive 
endoderm and 
prechordal plate 
 
 
(Vincent et al., 
2003) 
 
Smad2 dex2-/- 
 
Epiblast-specific 
 
Cardiac looping defect 
 
(Heyer et al., 
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deletion 
 
1999) 
 
Smad4 -/- 
 
Epiblast-specific 
deletion 
 
 
Midline defects in 
anterior primitive streak 
derivatives, 
looping defect of the 
heart 
 
 
(Chu et al., 
2004) 
Table 3.1 Key phenotypes in experimental mouse models of Smad genes in the TGF-β 
signaling pathway. 
 
 
Smad2/3 and Smad4 loss-of-function defects share phenotypic similarities 
with epiblast-specific Trim33 mutants 
Comparison of germline Smad2/3 and Smad4 mutants show overlapping 
phenotypes with few differences in tissue specificity (Table 3.1). Smad2 defects 
phenocopy mesendoderm defects and other phenotypes of Nodal and Activin 
receptor mutants; consistent with the fact that both Nodal/Activin receptors 
transduce signals via Smad2/3 and Smad4 (Conlon et al., 1994) and (Table 1.1). 
Within the Smad2 mutants, loss of Smad2 in a background of wild type extra 
embryonic tissues does not result in defects of mesendoderm induction, 
indicating that mesoderm induction is independent of Smad2 function in the 
embryo proper but a result of Smad2 function in the extra embryonic tissues.  
 Compared to Smad2 and Smad4 germline mutants, Trim33 germline 
mutants survive slightly longer up to E9, i.e. past neurulation and into the early 
somite stage (Kim and Kaartinen, 2008). 
 
It is critical to note that concurrent loss of Smad2 and Smad3 highlights 
redundancy as well differential regulation and dose sensitivity to TGF-β signals in 
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morphogenesis as demonstrated by phenotypes observed in compound 
Smad2/3 mutants. The early cardiac looping defects observed in compound 
heterozygous Smad2/3 mutants and epiblast-specific Smad2dex2-/- as well as 
epiblast-specific Smad4-/- mice implies that early cardiac morphogenesis is 
sensitive to TGF-β signaling dose and is consistent with cardiac defects and 
spatio-temporal role of Trim33 in the embryo proper described in Chapter 5 here. 
 
Although epiblast-specific Trim33 mutants clearly advance beyond the cardiac 
looping stage, similarity with the tissue type affected in the epiblast-specific 
Smad2 and Smad4 mutants implies that Trim33, Smad2/3 and Smad4 regulate 
identical or overlapping processes in cardiac morphogenesis.  
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CHAPTER 4 
Trim33 function at late gastrulation is required for normal embryogenesis: 
implications for cardiac development 
 
Abstract 
TGF-β superfamily signaling plays important, pleiotropic roles in development as 
well as tissue homeostasis. TGF-β signaling is tightly regulated in a context-
specific manner, and thus relatively subtle perturbations in TGF-β signaling 
strength result in a spectrum of birth defects and disease phenotypes of varying 
severity. In the canonical TGF-β pathway, receptor-regulated RSmads (Smad2/3) 
and Smad4 differentially mediate signal duration and intensity. However, the 
precise mechanisms by which Smad-dependent TGF-β signaling is regulated are 
still to be elucidated. Here, I show that Trim33 - a co-regulator of both activated 
TGF-β RSmads and Smad4 controls both visceral endoderm maturation and pre-
cardiac mesoderm differentiation. Epiblast-specific Trim33 mutants die during the 
second half of gestation as a result of ensuing cardiac failure. Reduction of 
Smad4 gene dosage in the Trim33-deficient background partially rescues the 
cardiac phenotype, indicating that excess of Smad-dependent TGF-β signaling 
contributes to the phenotype. My results imply that Trim33 is required for 
appropriate early mesendoderm differentiation soon after its induction, and that in 
more committed cell lineages Trim33 is dispensable. 
 
 
	   33	  
Introduction 
TGF-β superfamily signaling is crucial for many important cellular functions 
during early embryogenesis, such as, maintenance of stem cell pluripotency and 
differentiation of progenitor cell populations (Wall and Hogan, 1994; Ying et al., 
2003). One of the first discovered and best characterized evolutionarily 
conserved TGF-β functions is Nodal-induced mesendoderm formation during 
gastrulation (Weeks and Melton, 1987). Upon Nodal binding to Activin receptor 
complexes, they become activated resulting in phosphorylation of receptor-
regulated RSmads, i.e. Smad2/3 (Derynck and Feng, 1997; Massague and 
Chen, 2000). Subsequently, phosphorylated (p) Smads2/3 form complexes with 
their obligate binding partner, the common Smad (CoSmad4, referred as Smad4 
here) and the pSmad2/3-Smad4 complexes accumulate into the nucleus, where 
they induce expression of mesendoderm master regulators (Gsc and Mixl1) 
(Reissmann et al., 2001; Xi et al., 2011).  
While Smad4, as the common Smad, was initially considered to function as a 
central hub coordinating all TGF-β superfamily signaling events, it soon became 
evident that TGF-β superfamily signaling can also occur without involvement of 
R- or CoSmads via the so called Smad-independent (non-canonical) 
mechanisms (Derynck and Zhang, 2003). Moreover, RSmad mutant phenotypes 
differ from, and in fact are often more severe than those of Smad4 (Sirard et al., 
1998; Wisotzkey et al., 1998) suggesting that RSmads can mediate Smad4-
independent signaling events (discussed in Chapter 2 and 3). Consistent with 
these findings, few p-RSmad binding partners that mediate Smad4-independent 
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TGF-β functions have been described (Descargues et al., 2008; He et al., 
2006b). One of them - Trim33 (Tif1gamma, Ectodermin), was first shown to 
regulate TGF-β responses in erythropoiesis distinctly from Smad4, via selective 
binding to activated RSmads (He et al., 2006a).  
Tripartite domain containing 33 (Trim33) belongs to the Tif1 subfamily of 
tripartite domain -containing proteins. In addition to the N-terminal tripartite 
domain (composed of a RING finger domain, two B-box zinc finger domains, and 
a coiled coil region), Trim33 contains a Smad binding region, and a tandem of 
PhD and Bromo domains at its C-terminal end (Venturini et al., 1999). These 
structural characteristics confer Trim33 both E3 ubiquitin ligase and chromatin 
binding abilities. Subsequent studies have shown that the effect of Trim33 on 
TGF-β signaling is plastic and highly context dependent. In epithelial and 
malignant cell lines, Trim33 is shown to repress TGF-β signaling by 
monoubiquitinating Smad4 via a mechanism that involves Trim33 - histone 
interactions (Agricola et al., 2011; Dupont et al., 2009). An opposite role for 
Trim33 in regulation of TGF-β signaling is shown in mesoderm induction. In this 
context, Trim33 promotes TGF-β signaling by functioning as a chromatin reader, 
which regulates access of RSmad/Smad4 transcriptional complexes to their bona 
fide response elements (Xi et al., 2011). A common theme in Trim33-regulated 
biological events seems to be that its function is limited to situations where 
differentiation of progenitor cell populations is required, and thus Trim33 has little 
or no relevance in homeostatic TGF-β responses. Concordantly, tissue-specific 
Trim33 mutants show defects in hematopoiesis (Falk et al., 2014; Quere et al., 
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2014), in malignant transformation (Aucagne et al., 2011; Pommier et al., 2015; 
Vincent et al., 2012) and in other physiological and/or pathological conditions 
where cellular plasticity in required and/or intense tissue remodeling takes place 
such as terminal differentiation of mammary epithelium and during lactation 
(Hesling et al., 2013). 
While germline Trim33 mutant mice die during or soon after gastrulation (Kim 
and Kaartinen, 2008; Morsut et al., 2010), the role of Trim33 in the embryo 
proper during post-gastrulation development remains largely unknown. Here I 
show that the loss of Trim33 in differentiating ES cells immediately after 
mesoderm induction results in formation of viable embryoid bodies (EBs) that 
show enhanced ability to beat spontaneously when compared to their wild-type 
equivalent counterparts. Trim33-deficient EBs displayed reduced expression of a 
number of genes involved in maturation of the visceral endoderm, while only a 
few genes were upregulated. One of the affected genes was Ankrd1, a marker 
for cardiac distress. Consistent with elevated Ankrd1 in vitro, epiblast-specific 
Trim33 mutant mouse embryos display atrio-ventricular septal- and myocardial 
defects, and die during the second half of gestation as a result of ensuing cardiac 
failure. My results imply that Trim33 is required for appropriate TGF-β-controlled 
early mesendoderm differentiation soon after its induction, and that in more 
committed cell lineages Trim33 is dispensable. 
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Experimental Procedures 
Ethics Statement 
This research was conducted in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes 
of Health. Experiments described here are specifically approved by the University 
Committee on Use and Care of Animals (UCUCA) at the University of Michigan-
Ann Arbor (Protocol Number: PRO00005004). 
Establishment of embryonic stem cell lines and EB culture 
Mouse embryonic stem cells (mESCs) were derived from Trim33FF: UbcCreERT2 
blastocysts as described in (Pieters et al., 2012); mESCs were passaged in 
serum-containing medium (Life Technologies, Cat. No. 16141-061), dissociated 
with TrypLE Express (Life Technologies, Cat. No. 12605-010) and maintained in 
serum replacement medium (Knock Out Serum Replacement Cat No. 10828-
010, Life Technologies) in a base medium of 1:1 Knock Out Dulbecco’s Modified 
Eagle’s Medium and Ham’s F12. Trim33FF:UbcCreERT2 mESCs were maintained 
in feeder-free culture conditions in the presence of 2i+LIF. 2i: PD0325901 
(Tocris) in final concentration of 0.4µM, CHIR99021 (Stemgent) in final 
concentration of 3µM and LIF: (1000X) ESGRO (Millipore ESG 1106) on 0.1% 
gelatin (Sigma, G1393) coated tissue culture plates. Embryoid body (EB) 
formation and differentiation were carried out per the ATCC protocol in 20% 
serum containing medium. Both media for non-differentiating and differentiating 
conditions were supplemented by Glutamine (GlutaMAX-l (100X), Life 
Technologies, Cat. No. 35050-061), β-mercaptoethanol (1000X, Life 
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Technologies, Cat. No. 21985-023) and Penicillin/Streptomycin (Life 
Technologies, Cat. No.15140-122).  
4-hydroxytamoxifen (4-OHT) (Sigma Cat. No. T176) was added at 
intended and precise time points in a concentration of 1 µg per mL of medium. 
Percentage of beating EBs were counted and averaged in 3 independent sample 
pairs, in 6 separate areas of each culture dish, at the same time point on Days 9, 
10 and 11 in a genotype-blind manner by 2 independent observers. 
For relevant experiments, control and Trim33-deficient EBs were treated 
with rhTGF-β3 (R&D Systems, Cat. No. 243-B3) and rh/m/rActivin A (R&D 
Systems, Cat. No. A338-AC) for 40 minutes in concentrations of 10ng/mL and 
100ng/mL respectively.  
Mice 
Trim33FF, Nkx2_5Cre, Mox2Cre, Sox2Cre, TCre and UbcCreERT2 and Smad4FF 
have been described earlier (Kim and Kaartinen, 2008; Moses et al., 2001; 
Perantoni et al., 2005; Tallquist and Soriano, 2000; Yang et al., 2002). Timed 
matings between Trim33KoWt and appropriate Cre+ males and Trim33FF or 
Trim33FWt female mice were set up to obtain Trim33FKo:Cre+ tissue-specific 
mutant embryos (Trim33cKo). Controls were either Trim33WtWt:Cre-  
or Trim33FWt:Cre- and on occasion Trim33FWt:Cre+ (Trim33cHet) where explicitly 
indicated.  
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Histology, immunohistochemistry 
Mouse embryos were harvested in sterile DBPS and fixed overnight in 
commercial 10% formalin or freshly made 4% paraformaldehyde in PBS at 4oC 
overnight (O/N). Samples for histology as well as immunohistochemistry were 
processed in a standard paraffin-embedding protocol. Briefly, embryonic tissues 
were washed, dehydrated, oriented in desired plane and embedded in fresh Blue 
Ribbon Tissue Embedding/Infiltration Medium (Leica Surgipath). 7µm serial 
sections were mounted on Superfrost plus slides (Fisher) and stored at room 
temperature or 4°C. Haematoxylin and eosin staining was performed using a 
standard protocol.  
 Myocardial thinning in embryonic hearts was quantified by measuring the 
thickness of compact myocardium in 3 independent sample pairs, in 6 separate 
areas per sample in serial sections. The thickness measurement was co-related 
with number of cell layers present by counting nuclei across the thickness of the 
wall; control measurements were consistent with previously described data 
(Sedmera et al., 2000).  
Immunoflourescent detection of hypoxia levels in oro-facial tissue sections 
was done using the HypoxyprobeTM-1 kit per manufacturer’s instructions; 
Hypoxyprobe detects reductive binding to 2-nitroimidazoles in hypoxic cells 
(Raleigh and Koch, 1990; Varghese et al., 1976). 
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In situ hybridization (ISH) 
DIG-labeled RNA probe for Trim33 was designed (385 bp, 1156 – 1539, refSeq 
NM_001079830) to span the targeting strategy for the targeted, Trim33-floxed 
allele in order to discriminate control and Trim33cKo embryos processed together 
for all experimental steps. Trim33 ISH probes were generated using a DIG-
labeled NTP mix (Roche Applied Sciences) according to manufacturer’s 
instructions, stored at −80, or −20°C diluted in hybridization buffer.  
Embryos for whole mount ISH were fixed in freshly thawed 4% paraformaldehyde 
in PBS O/N, washed in PBST, dehydrated and stored in 95% methanol: 5% 
PBST at −20°C. Samples thus prepared were Proteinase K-treated (Invitrogen, 
Cat. No 25530-049 in final concentration of 10µg/ml), post-fixed and pre-
hybridized rotating for at least 1 hour in standard non-SDS-based hybridization 
buffer, pH 5, at 70°C. Probe was added in a final concentration of 0.1–1ng/µl and 
left rolling overnight. Embryos were subsequently washed in a roller set-up for 20 
minutes each, three times in preheated hybridization buffer at 70°C, once in 
hybridization buffer/TBST, then in at least 6 changes of TBST at room 
temperature (RT) over 1 hour, blocked in 0.05% Roche block (one hour) and 
rocked O/N at 4°C with α-alkaline phosphatase (AP) labeled-DIG Fab fragments 
(Roche Applied Sciences,1:2000–5000). Samples were thoroughly washed with 
several changes of TBST the next day at room temperature and then O/N at 4°C. 
On Day 4, samples were equilibrated for 10 minutes (RT) twice in NTMT, pH 9.5 
in a roller set up and stained with BM Purple AP substrate at RT in the dark for 
several hours. Stained embryos were washed thoroughly in PBS, fixed in 4% 
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paraformaldehyde and stored at 4°C. Stained embryos were imaged and 
processed for routine genotyping post-staining, post-fixing upon satisfactory 
documentation of ISH results.  
Real-time PCR 
Equivalent amounts/number of EBs were collected in 100-200 µl of commercially 
available (Qiagen) RLT buffer at intended time points. RNA was isolated using 
(Qiagen RNesy Mini Kit Cat. No 74104) and cDNA was synthesized using 
Omniscript RT(Qiagen Cat. No.205111) per standard methods. Taqman Assay 
reagents (Life Technoligies) were used for all targets except Actb, which was 
used to normalize expression levels. Universal Probe Library-based assays 
(Roche Applied Science) with gene-specific primer sequences were generated 
using the manufacturer’s online algorithm, details are below. 30µl assays 
dispensed in TaqMan Universal PCR 2X master mix (Applied Biosystems) with or 
without universal probe were quantified using Applied Biosystems ABI7300 PCR 
and ViiA7 detection systems and software. All Ct values were manually checked. 
cDNA was diluted where necessary to avoid Cts lower than 18. At least three 
independent mutant samples and littermate and stage matched controls were 
assessed for each genotype/condition.  
Taqman assay # are indicated in parenthesis: Ankrd1 (Mm00496512_m1), Apob 
(Mm01545150_m1), Apoc2 (Mm00437571_m1), Gsc (Mm00650681_g1), Isl1                 
(Mm00517585_m1), Mttp (Mm00435015_m1), Nestin (Mm00450205_m1), 
Pouf51 (Mm00658129_gH), Tbx5 (Mm00803518_m1), Trim33 
(Mm01308695_m1).  
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Actb: Forward Primer (tgacaggatgcagaaggaga), Reverse Primer      
(cgctcaggaggagcaatg), Universal Probe #106 
RNA-Sequencing 
Equivalent amounts/number of EBs were collected at Day 7, comprising Trim33-
deficient and control pairs (n=2 independent pairs), in 100-200 µl commercially 
available (Qiagen) RLT buffer. Total RNA was isolated using Qiagen RNesy Mini 
Kit Cat. No 74104. mRNA and sequencing libraries were prepared by the 
University of Michigan DNA Sequencing Core and reads generated on Illumina 
HiSeq2000. After quality assessment per sample, single-end, 52 base pair reads 
were aligned to mm9 (Mus musculus assembly July 2007) using STAR RNA Seq 
aligner (Dobin et al., 2013). On average, input reads ranged between 35 million 
to 42 million across all samples, out of which approximately 80 per cent reads 
mapped uniquely. Read counts for differential expression were obtained using 
HTSeq program. Differential expression analyses were performed using the 
DESeq program in R Statistical Package. 
https://bioconductor.org/packages/3.3/bioc/vignettes/DESeq/inst/doc/DESeq.pdf.  
Echocardiography 
At day 11.5 dpc, pregnant Trim33FF female mice crossed with 
Trim33KoWt:Sox2Cre+ male mice were anesthetized in an enclosed container filled 
with 4% Isoflurane and the mice were then placed on a warming pad to maintain 
body temperature. 1–1.5% Isoflurane was supplied via a nose cone to maintain 
surgical plane of anesthesia. Hair was removed from the upper abdominal and 
thoracic area with depilatory cream. Both uteri were surgically accessed and 
	   42	  
each embryo was monitored for ECG with non-invasive resting ECG electrodes. 
Two-dimensional, M-mode, Doppler and tissue Doppler echocardiographic 
images were recorded using a Visual Sonics' Vevo 770 high resolution in 
vivo micro-imaging system for each embryo in a genotype-blind manner. Data 
from each embryo recording were systematically indexed and genotyping 
material was collected to correlate with findings after the actual experiment. Data 
were recorded for following parameters: heart rate (HR) beats per minute (BPM), 
velocity mm per second for both dorsal aorta (DA) and umbilical artery (UA), 
Velocity Time Interval (VTI) in mm for DA and UA, Ejection Time (ET) in msec 
measured in the DA. Actual measurements obtained are summarized in table 3 
below.  
Western blot and Immunoprecipitation  
Western blot and Immunoprecipitation studies using antibodies against Trim33 
(Bethyl # A301-060A), Smad2 (D43B4) XP (Cell Signaling#5339), pSmad2/3 
(Cell Signaling #8828), Smad4 (B-8) (Santa Cruz #sc7966) and Atcb (Sigma 
#A1978;) were carried out using standard procedures and in accordance with 
manufacturer’s instructions. For Western blotting, EBs were lysed in Pierce IP 
Lysis Buffer (ThermoScientic, Prod# 87787) supplemented with sodium fluoride 
(NaF) and sodium ortho vanadate (Na3VO4) to a final concentration of 1mM. 
Lysates were prepared per manufacturer’s instructions and used in equivalent 
amounts for Western blotting. Both Trim33-deficient and control samples were 
treated with TGFβ3 and Activin as described earlier and used as positive controls 
	   43	  
to demonstrate alterations in Smad4 and activated (phosphorylated) Smad2/3 
levels.  
For immunoprecipitation, EBs were gently dissociated on Day 4, and plated onto 
gelatin-coated dishes. On the following day the dishes were transfected either 
with the superfolder-gfp (negative control (Pedelacq et al., 2006)) or Trim33-flag 
expression vectors using ViaFect transfection reagent (Promega Cat No. E4981), 
according to manufacturer’s instructions. Two days later the cells were lysed in 
Pierce IP-lysis buffer (cat no. 87787). The cleared lysates were 
immunoprecipitated using a rabbit monoclonal anti-Flag antibody (Cell Signaling 
Technology #14793) and washed precipitates were analyzed using western 
blotting as outlined above. 
Analysis of erythroid progenitors 
Embryonic livers were harvested at E13 and mechanically dissociated by 
pushing with a syringe through a 70µm cell strainer. Cells were immunostained at 
4oC in PBS:0.5 % BSA in the presence of PE-conjugated anti-Ter119 (BD-
Pharmingen cat#553673) and FITC-conjugated anti-CD71 (BD-Pharmingen 
cat#553266) antibodies. The cells were washed and analyzed on flow cytometer 
BD FACSAria II from BD Biosciences.	  
Statistical Analyses 
For histological data and expression (qRT-PCR) assays, three or more samples 
were analyzed. Averages, standard error and probability (Student’s t-test) were 
calculated and p values of less than or equal to 0.05 was marked as significant. 
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Results 
4-OHT-induced deletion of Trim33 post mesoderm induction in vitro reveals 
defects in extra-embryonic endoderm and cardiac mesoderm 
Earlier studies have elucidated the role of Trim33 in gastrulation and 
mesendoderm induction (Morsut et al., 2010; Xi et al., 2011). Using the mES cell-
derived EB system, we examined the role of Trim33 in stages following germ 
layer specification. To this end, we established embryonic stem cell lines from 
Trim33FF:UbcCreERT2 blastocysts as described by (Pieters et al., 2012) (Figure 
4.1). The UbcCreERT2 transgene (Ruzankina et al., 2007) was used to activate 
Cre-induced recombination by 4-hydroxytamoxifen (4-OHT) at desired time 
points resulting in temporally controlled deletion of the targeted, floxed Trim33 
alleles (Kim and Kaartinen, 2008). Since our objective was to investigate the role 
of Trim33 in normal post-gastrulation events as closely mimicking in vivo 
embryogenesis as possible (within the limits of the embryoid body technique), ES 
cells were allowed to undergo spontaneous differentiation in suspension culture 
on ultra-low attachment dishes as described in 
(http://diyhpl.us/~bryan/irc/protocol-online/protocol-
cache/Embryoid_Body_Formation.pdf). 
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Figure 4.1. Experimental design for derivation of Trim33FF:UbcCreERT2 mouse ES 
cells:Trim33FF:UbcCreERT2 blastocysts were harvested from the mouse cross described and mES 
cells were derived using a pluripotin-based protocol described in (Pieters et al., 2012). 
 
 
4-OHT was added to the culture media to induce Cre activation at day 4 after 
initiation of differentiation (Figure 4.2B). Expression levels of the mesodermal 
marker gene Gsc were comparable on Days 5 and 7 between 4-OHT-induced 
and non-induced control cultures demonstrating that this treatment regimen 
allowed equivalent mesoderm induction in both 4-OHT negative and positive 
cultures (Figure 4.2C). Although the Trim33-floxed allele was effectively 
recombined and mRNA repressed within 6 hours after 4-OHT-induction (data not 
shown), Trim33 protein levels remained unaltered at least for the next 24 hours 
(Figure 4.2A).  
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Figure 4.2. Optimization of conditions and time point of Trim33 deletion in vitro. 
(A) Trim33 protein is stable for at least 24 hours after 4-OHT induced Cre-recombination in 
Trim33FF:UbcCreERT2 mESCs. (B) Schematic presentation to highlight the timing of 4-OHT 
administration (C) Day 4 induction of Cre in Trim33FF:UbcCreERT2 EBs results in comparable 
initiation of differentiation assessed by Pouf51 expression and comparable mesoderm induction 
assessed by Gsc expression. Blue bars represent Pouf51 expression (dark blue = control, light 
blue = Trim33 deficient EBs); brown bars represent Gsc expression (dark brown = control, tan = 
Trim33 deficient EBs) 
 
 
Morphological differences between Trim33FF:UbcCreERT2;4-OHT+ (herein Trim33 
deficient EBs) and control EBs started to become evident on day 8. Trim33 
deficient EBs were smaller and showed less expanded ‘balloon-like’ cystic 
appearance. Both mutant and control EBs displayed beating clusters between 
days 9 and 11; however, the number of contracting or beating EBs was higher in 
4-OHT+ versus 4-OHT- cultures (Figure 4.3C).  
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Figure 4.3. Trim33 deficient EBs show enhanced beating clusters in differentiating culture. 
(A) Control EBs, Trim33FF:UbcCreERT2;4-OHT- and (B)Trim33 deficient EBs, 
Trim33FF:UbcCreERT2;4-OHT+ (day4 induction) are morphologically similar at day 7, however (C) 
show an increased number of beating cell clusters between days 9-11. Error bars in C= +/- SEM. 
 
I harvested both the Trim33-deficient and control EBs at day 7 (when the mutants 
and controls still showed grossly comparable appearance) and subjected them to 
genome-wide RNA-Seq transcriptome analysis (Figure 4.4). Of Trim33-
dependent genes (>2-fold change; p<0.05), 62 were down regulated and only 10 
were up regulated (Table 1 in Appendix 1). Confirmation of differential expression 
of selected genes by qRT-PCR provided results that were fully consistent with 
those obtained from the RNA-Seq screen (Figure 4.5). Moreover, none of the 
germ layer marker genes were differentially expressed (DE) in the screen, 
validating our intended model.  
My data shows that a large number of differentially expressed genes (22%) 
are involved in various aspects of lipid metabolism. These include the gene 
encoding microsomal triglyceride transport protein (Mttp) and genes encoding 
several different apolipoproteins. During early embryogenesis these genes are 
mostly expressed in the extraembryonic endoderm, where many of them display 
critical non-redundant functions as demonstrated by knockout studies. Mttp 
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homozygous mutants die at mid gestation and half normal dose of Mttp is also 
not compatible with survival (Huang et al., 1995; Raabe et al., 1998). Moreover, 
an established extra-embryonic endoderm marker Afp (Krumlauf et al., 1986) 
was almost 30-fold down-regulated in Trim33 deficient EBs when compared to 
control EBs. Eight of the differentially expressed genes have been shown to 
possess transporter activity and 10 of them have been implicated in maintenance 
of metabolic homeostasis. 
Of the up-regulated genes Shisa3 (4.4-fold up) is a putative transmembrane 
inhibitor of Wnt signaling (Chen et al., 2014) and Dusp4 (2-fold up) is a regulator 
of the Map kinase pathway (Balko et al., 2013). Nipal1 (11-fold up) has been 
implicated in pathogenesis of exencephaly and Ankrd1 (4-fold up) is a 
(Bogomolovas et al., 2015) marker for cardiac distress. To conclude, 
morphological and expression profiling experiments in EBs suggested that 
abrogation of Trim33 after mesoderm induction results in changes in the extra-
embryonic endoderm and cardiac mesoderm. 
 
Figure 4.4. Differentially expressed genes in Trim33-deficient EBs at day 7 in 
differentiation. Trim33FF:UbcCreERT2 mESCs were allowed to differentiate and 4-OHT was added 
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to the experimental sample at Day4, inducing Trim33 deletion after mesoderm induction.  Control 
EBs were Trim33FF:UbcCreERT2 ; 4-OHT-. EB samples were collected at day 7 for RNA-Seq 
trancriptomic analyses. Statistically significant, differentially expressed genes include Trim33  
(expected positive control, highlighted in blue), Visceral Endoderm (VE) markers highlighted in 
yellow and Ankrd1, highlighted in red, n=2 independent sample pairs. 
 
 
Figure 4.5. qRT-PCR validation of differentially expressed genes in RNA-Seq screen. 
Among the differentially expressed genes (Figure 5.4 above and Appendix 1, Table 1), Mttp, 
Apob, Apoc, Ankrd expression was assayed by qRT-PCR in Trim33-deficient and control EBs, in 
exactly same samples as in Figure 5.4. All 4 genes assayed show expected fold change 
consistent with the results from RNA-Seq data in Figure 5.4. *p < 0.05, error bars = +/- SEM, n = 
3 independent sample pairs. 
 
Trim33 interacts with activated Smad2 in differentiated ES cells and Trim33 
deficiency results in sustained attenuation of canonical TGF-β signaling 
To characterize the role of Trim33 in regulation of TGF-β signaling during 
developmental events following mesoderm induction, Flag-tagged Trim33 was 
transiently expressed in day 7 EBs. Co-immunoprecipitation assay demonstrated 
that Flag-tagged Trim33 formed a complex with Smad2, and that this complex 
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formation is further strengthened by Activin induction (100ng/mL, 40 minutes). 
Under these conditions, complex formation between Trim33 and Smad4 was not 
detected (Figure 4.6). 
 
 
Figure 4.6. Trim33 interacts with activated Smad2 in differentiated ES cells. Flag-tagged 
Trim33 was transiently expressed in day 7 EBs. Flag-tagged Trim33 formed a complex with 
Smad2 in the co-immunoprecipitation assay; this complex formation is further strengthened by 
Activin induction. Immunoprecipitates were analyzed for the presence of bound proteins using 
Western blotting. 
 
To determine the effect of Trim33 on regulation of TGF-β signaling after 
mesoderm induction, I stimulated 4-OHT induced and non-induced EBs with 
Activin or TGF- β and compared C-terminal Smad2 phosphorylation levels 
between control and Trim33-deficient samples with or without ligand stimulation. 
Both control and Trim33-deficient samples responded to ligand stimulation; 
however, the level of C-terminal Smad2 phosphorylation was less in both 
unstimulated and stimulated Trim33 deficient samples (Figure 4.7). 
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Figure 4.7. Trim33-deficient EBs show reduction in baseline Smad2 phosphorylation and 
decrease in Smad4 protein levels. Trim33FF:UbcCreERT2 mESCs in differentiation: 4-OHT was 
added in the experimental sample at day 4 and both Trim33 deficient and control, 4-OHT- EBs 
were harvested at day 7. This figure shows results from Western gel/blot analyzing protein 
lysates for Smad4, Smad2 phosphorylation, and Smad2 protein levels. Activin and Tgfβ 
stimulation was 40 minutes in appropriate samples. 
 
These experiments show that Trim33 interacts with activated Smad2 in 
differentiated ES cells and that Trim33 deficiency results in sustained down-
regulation of canonical TGF-β signaling. 
 
Deletion of Trim33 in the mesodermal lineage in vivo does not result in 
obvious developmental phenotypes 
Since Trim33-deficient EBs showed differences gene expression of pre-
cardiac/cardiac mesoderm, I hypothesized that deletion of Trim33 in the 
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mesodermal lineage using TCre (Perantoni et al., 2005) would result in 
developmental defects in mouse embryos. However, living Trim33FF:TCre mutant 
embryos without overt phenotypes were obtained at the expected Mendelian 
frequency at all stages examined (E13-E18). Detailed histological analysis 
revealed a subtle delay in the formation of the inter-ventricular septum at E13 
(data not shown). In addition, we used Nkx2-5Cre and Tie2Cre drivers to delete 
Trim33 in pre-cardiac mesoderm and in mesoderm-derived endothelium, 
respectively. In both cases, mutant embryos were obtained without any 
detectable external or histological phenotypes (data not shown). These 
experiments suggest that Trim33 is not required for development of mesodermal 
cell lineages after their initial specification.  
 
Epiblast–specific Trim33 mutants are embryonic lethal and show cardiac 
and craniofacial defects 
 Since mesoderm-specific Trim33 mutants showed no clear developmental 
phenotypes, I first confirmed that Trim33 is expressed in immediate post 
gastrulation stages in mouse embryos (Figure 4.8). I observed strong ubiquitous 
Trim33 expression at E7-E8.5 in the embryo proper and less intense expression 
in extra embryonic tissues. 
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Figure 4.8. Trim33 and Brachyury (T) expression in the E8.5 mouse embryo. In situ 
hybridization of control (left in A, B) and epiblast-specific Trim33 mutants (Trim33FF: Sox2Cre+), 
right in A, C) at E8.5 for Trim33 and Brachyury (T) expression. Trim33 is ubiquitously expressed 
in the mouse embryo at E8.5. The Trim33 ISH probe is designed to span the sequence within the 
targeted, Trim33-floxed allele; epiblast-specific Trim33 mutants show abrogation of Trim33 
expression as expected, confirming the putative Trim33 expression pattern at this mouse 
embryonic stage. Brachyury (T) expression is comparable in controls (D, F) epiblast-specific 
Trim33 mutants (E, G).  
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Next, I proceeded to delete Trim33 conditionally over a preceding time window in 
embryonal tissues using the Sox2Cre driver, which recombines in the epiblast 
during gastrulation (Hayashi et al., 2002). Trim33 mRNA expression was 
completely abolished in Trim33FF:Sox2Cre mutants. Moreover the mesoderm 
marker Brachyury(T) is expressed on comparable level and shows a similar 
pattern of expression (Figure 4.8) in Trim33FF:Sox2Cre  mutants and controls 
suggesting that Trim33 deficiency does not grossly affect mesoderm induction 
and gastrulation. Before E11.5, Trim33FF:Sox2Cre mutant embryos did not show 
obvious morphological defects and they were obtained almost at the expected 
Mendelian frequency  (60 of 278). However, at later stages starting at E13, I 
obtained fewer than expected mutant embryos with very few surviving through 
E17-18 (Figure 4.9A). No viable Trim33FF:Sox2Cre embryos were obtained at 
birth. Among the mutant embryos collected at E13 (n>31), I frequently detected 
cardiac edema (Figure 5.9B) and occasionally saw embryos that displayed 
excencephaly (n=2, data not shown). Moreover, all the Trim33FF:Sox2Cre 
mutants that survived beyond E15.5 showed cleft palate (Figure 4.10 A and B). 
Previous work from our group has demonstrated that deletion of Trim33 alone in 
tissue types that contribute to palate formation such as the neural crest, palatal 
epithelium and palatal ectomesenchyme is not sufficient to cause cleft palate or 
palatal phenotypes (Lane et al., 2015). Since there was no substantial evidence 
of a genetic cause, we next assessed whether a systemic cause such as 
hypoxia, which is also known to be a causative mechanism of cleft palate was 
involved. Palatal shelves from epiblast-specific Trim33 mutants showed 
	   55	  
enhanced binding to Hypoxyprobe, which reliably detects tissue hypoxia levels 
(Figure 4.10 C and D). Western blot assay to detect pSmad2 and pSmad1/5/8 in 
control and Trim33 mutant primary palatal ectomesenchymal cells after TGF-β 
stimulation shows reduction pSmad2 levels in the mutant samples, with further 
reduction in the baseline pSmad2 levels in non -TGF-β-stimulated mutant 
samples (Figure 4.10.E). 
 
Figure 4.9. Epiblast-specific Trim33 mutants die around E13. (A) Survival data across 
embryonic stages for epiblast-specific Trim33 mutants versus controls. (B) Cardiac edema in 
epiblast-specific Trim33 mutant – representative image.  
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Figure 4.10. Cleft palate defect in epiblast-specific Trim33 mutants occurs as a 
consequence of hypoxia. Epiblast-specific Trim33 mutants (Trim33FF: Sox2Cre+) that survived 
beyond E14 showed cleft palate with high frequency, hypoxic regions in the craniofacial tissues 
and reduced level of RSmad phosphorylation in primary palatal epithelial cells. Frontal sections of 
control (A) and mutant (B) embryos at E17, arrow in B points to the cleft between palatal shelves. 
Frontal sections of control (C) and mutant (D) embryos at E13 show immunostaining (red signal) 
to detect hypoxyprobeTM -1, counterstained with DAPI (blue). White arrows point to positively 
staining regions in palatal shelves in (D); asterisks in (C, D) depict similar staining in the tongue 
tissue. (E) Western blot assay to detect pSmad2 and pSmad1/5/8 in control and Trim33 mutant 
primary palatal ectomesenchymal cells after TGF-β stimulation shows reduction in baseline (non-
stimulated) pSmad2 levels in the mutant samples.  
	   57	  
Gestational death in mouse embryos at E10-E13 has been attributed to two most 
likely causes: a defect in cardiac/circulatory function and/or a hematopoietic 
deficiency (Papaioannou and Behringer, 2012). Previous studies have shown 
that Trim33 can promote erythroid differentiation (He et al., 2006b) and regulate 
transcriptional elongation of erythroid genes (Bai et al., 2010; Bai et al., 2013). 
Therefore, we quantified premature and mature erythrocytes in control and 
Trim33 mutant at E13.5 by using a FACS assay (Koulnis et al., 2011). While we 
detected a modest reduction in both CD71HITer119HI and CD71LOTer119HI cell 
populations marking early and late erythroblasts, these changes alone are too 
subtle to result in embryonic death that we observe in epiblast-specific Trim33 
mutants (Figure 4.11).  
 
Figure 4.11. Epiblast-specific Trim33 mutants show a modest reduction in the number of 
erythroblast populations. Freshly dissociated epiblast-specific Trim33 mutant 
(Trim33FF:Sox2Cre+) and control livers were dissociated and labeled with FITC-conjugated 
antiCD-71 and PE-Conjugated antiTer-119 monoclonal antibodies to assess early and late 
erythroblasts. Labeled cells were analyzed using flow cytometry, dead cells were excluded from 
analysis. Error bars = +/- SD. 
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Next, we compared cardiac function between control and epiblast-specific Trim33 
mutants at E11.5 by using echocardiography. This assay identified 2 out of 4 
Trim33FF:Sox2Cre mutants with a cardiac failure (Table 4.1), which together with 
my finding of cardiac edema often associated with the cardiac failure (Figure 
4.9B), led us to investigate the cardiac phenotype of developing 
Trim33FF:Sox2Cre mutants in detail. 
 
Control 
# 
 
Heart Rate 
 
Trim33FF:Sox2Cre+ 
# 
 
Heart Rate 
 
1 
 
71 
 
1 
 
77* 
 
2 
 
41 
 
2 
 
88* 
 
3 
 
91 
 
3 
 
35 
 
4 
 
113 
 
4 
 
194 
 
Mean 
 
 
52.40 
 
- 
 
115 
 
ST DEV 
 
 
59.79 
 
- 
 
112 
 
Table 4.1. Ex utero echocardiography data in E11.5 control and epiblast-specific Trim33 
mutants. Echcardiography recordings detected arrhythmia (marked *) in 2 out of 4 epiblast-
specific Trim33 mutants (Trim33FF:Sox2Cre+) as compared to their littermate controls. 
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Figure 4.12. Epiblast-specific Trim33 mutants display severe cardiac defects. (A-E) 4-
chambered views of control (A, B) and Trim33FF:Sox2Cre+ mutant (C-E) hearts at E13.5. (B, D) 
show magnified image of inset in (A, C) showing the compact myocardial layer; area highlighted 
was used for quantification in (F); black arrowheads in C, E point to VSD, black arrow in E points 
to ASD. (F) Quantification of myocardial thickness in the compact myocardium of ventricular walls 
in controls (bar labeled C) and epiblast-specific Trim33 mutant (bar labeled M). (G-J) 4-
chambered view of the embryonic control (G) and surviving mutant hearts (H-J) at E17. (H, 
Trim33FF:Sox2Cre+ mutant.  (I, J) Trim33FF:Mox2Cre+ mutants (Mox2Cre is a less robust epiblast-
specific driver). All mutants show defects in the ventricular myocardial wall (inset in H-J. 
Moreover, VSDs were commonly detected (arrowhead in H and inset in J).  Error bars = +/-SEM, 
*p<0.05. 
 
Histological serial sections of cardiac tissues showed that all the examined 
mutants show either membranous or muscular ventricular defects (VSDs) and 
thinning of the ventricular myocardium (Figure 4.12). While differences in septum 
formation and myocardial thickness were not apparent in earlier stages (E9-E11), 
they were clearly evident at E13 (Figure 4.12 A-C).  In addition, the mutants 
showed atrial-septal defects (ASD) with variable penetrance (Figure 4.12 E). The 
VSD and myocardial defects were recapitulated independently by using the 
Mox2Cre driver line, which shows a chimeric recombination pattern in the 
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epiblast (Tallquist and Soriano, 2000) (Figure 4.12 I, J). Consistent with my 
finding in EBs in vitro, expression levels of Ankrd1, a novel marker for cardiac 
pressure overload and failure (Bogomolovas et al., 2015), were increased in 
Trim33FF:Sox2Cre+ mutant hearts at E10.5  when compared to control tissues 
(Figure 4.13 B). Collectively, these findings suggest that the death of epiblast-
specific Trim33 mutants around E13 results from deficiency of cardiac function, 
likely cardiac failure. 
 
Expression changes in epiblast-specific Trim33 mutants 
Myocardial development and heart morphogenesis are orchestrated by an array 
of evolutionary conserved transcription factors (McCulley and Black, 2012). 
Among these, Gata4, Nkx2-5, Isl1 and Tbx5 have been shown to be of particular 
importance. I therefore used a candidate approach and RNAs extracted from 
E8.5 embryos to analyze whether expression levels of any of these factors were 
altered in Trim33FF:Sox2Cre+ mutants. My results show that both Tbx5 and Isl1 
are down regulated in epiblast-specific Trim33 mutants as compared to littermate 
controls, suggesting that reduced expression of these factors may contribute to 
observed myocardial and ventricular septal defects (Figure 4.13 A) 
 
Given the coinciding time points in embryonic lethality with Trim33FF:Sox2Cre+ 
mutants and Mttp homozygous mutants (Raabe et al., 1998) and my expression 
findings displaying reduced Mttp in Day7 EBs in vitro, I investigated whether 
Mttp, together with other genes associated with lipid metabolism, would show 
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altered expression in Trim33-mutant embryonic tissues at E8.5. My results show 
that while Apob and Apoc2 were not affected byTrim33 deficiency (data not 
shown), however, Mttp expression levels were significantly reduced at E8.5 
(Figure 4.13 A). 
 
Figure 4.13. Tbx5, Isl1, Mttp expression is down regulated in epiblast-specific Trim33 
mutants at E8.5. Relative mRNA expression (A) in epiblast-specific Trim33 mutant and control 
whole embryo samples at E8.5 and (B) in E10.5 hearts in epiblast-specific Trim33 mutants and 
heterozygote controls.The key cardiac transcription factors Tbx5 and Isl1,Mttp - a critical regulator 
of lipid metabolism and Ankrd1, a cardiac failure marker is down-regulated in epiblast-specific 
Trim33 mutant embryos. Ankrd1 is up regulated in later stages at E10.5 hearts, shown in (B). 
Error bars = +/- SEM, *p <0.05. 
 
The lethal phenotype of Trim33 embryos can be partially rescued by Smad4 
haploinsufficiency   
While Trim33 has been shown to regulate many cellular processes in a highly 
context-dependent manner (Ferri et al., 2015; Isbel et al., 2015; Wang et al., 
2015; Xue et al., 2015), perhaps, the most well-documented is its role as either a 
negative or positive modulator of TGF-β signaling (Dupont et al., 2009; Dupont et 
al., 2005; He et al., 2006b; Morsut et al., 2010; Xi et al., 2011). To examine 
whether Smad-dependent TGF-β signaling contributes to the observed epiblast-
specificTrim33 mutant lethal phenotype, I generated epiblast-specific Trim33 
mutants, which were heterozygotes for the Smad4 gene 
Control
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(Trim33FF:SmadFWt:Sox2Cre+), and compared their survival rate and cardiac 
phenotype to those of Trim33FF:Sox2Cre+ mutant and Cre-negative control 
littermates. At E13, the survival rate of epiblast-specific Trim33 mutants was less 
than 50% of the expected frequency, while the corresponding frequency of 
Trim33FF:SmadFWt:Sox2Cre+ mutants was more than 100% (Figure 4.14A).   
 
 
Figure 4.14. Lethal phenotype of epiblast-specific Trim33 mutants is partially rescued by 
Smad4 heterozygosity.  (A) Bar graph depicting surviving Trim33FF:Sox2Cre+ and 
Trim33FF:Smad4FWt:Sox2Cre+ mutants at E13. (B-D) 4-chamber view of control (B) and two 
Trim33FF:Smad4FWt:Sox2Cre+ mutant (C, D) hearts. The mutant in C shows normal thickness of 
the compact myocardium (arrows in B and C), while another mutant littermate (D) shows 
characteristic thin myocardium (black arrowhead) and deficient septal growth (blue arrowhead) 
consistent with that observed in Trim33FF:Sox2Cre+ mutants. 
 
These data demonstrate that the lethal cardiac phenotype of the epiblast-
specific Trim33 mutants can be partially rescued by Smad4 haploinsufficiency 
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suggesting that Trim33 regulates Smad-dependent TGF-β superfamily signaling 
in mouse embryos after mesoderm induction. 
 
Discussion 
In this study, we used ES cell-based in vitro differentiation assays and tissue-
specific knockout mouse models to investigate the role of Trim33 in mouse 
development. We found that deletion of Trim33 in embryoid bodies after 
mesoderm induction results in morphological, functional and molecular changes 
in visceral endoderm and cardiac mesoderm cells in vitro. Epiblast-specific 
Trim33 mutants display a spectrum of cardiac defects and die after mid-
gestation. The said Trim33 phenotype is partially rescued by Smad4 
haploinsufficiency suggesting that in late-gastrulation embryos Trim33 represses 
canonical TGF-β signaling. 
 
Trim33 regulates extraembryonic endoderm development in vitro 
During normal embryogenesis, the extraembryonic endoderm (ExEn) gives rise 
to the parietal endoderm (PE) and visceral endoderm (VE), which provide 
nutrients and instructive morphogen signals for appropriate cell fate and 
patterning decisions (Bielinska et al., 1999). The anterior visceral endoderm 
(AVE) forms a distinct population of VE cells and plays a critical role in 
positioning of the head and heart (Madabhushi and Lacy, 2011).  
Here we show that when Trim33 is deleted in EBs after mesoderm induction, 
the mutant EBs are viable and form beating clusters. However, at later stages the 
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mutant EBs show less-expanded cystic appearance. Already before the 
morphological differences are obvious, many VE associated genes are 
dramatically down-regulated in Trim33-deficient EBs. These include VE markers 
Afp, and Ttr (Fujikura et al., 2002) and critical regulators of VE differentiation and 
lipoprotein biosynthesis Hnf4a and Mttp, respectively (Morrisey et al., 1998; 
Raabe et al., 1998). Moreover, the VE-specific Amn and Cubn genes, which 
encode multi-ligand endocytic receptors that mediate uptake of nutrients 
(Christensen and Birn, 2002), lipids and cholesterol in particular, and several 
apolipoprotein genes are expressed at much lower levels (>20-fold down-
regulated) in Trim33-deficient EBs as compared to control EBs. One of the 
primary functions of the VE is to provide nutrition to the embryo during 
neurulation (Zohn and Sarkar, 2010). Therefore it is of interest that Trim33 
germline mutants die during neurulation as shown in two independent studies 
(Isbel et al., 2015; Kim and Kaartinen, 2008).  
 It is noteworthy that Dkk1, Cer1, Lefty1 and Hex, established markers for the 
AVE, and Gata4 and Gata6, the determinants of ExEn specification, were not 
differentially expressed between mutant and control EBs in our global 
transcriptomic analyses. Gata4 expression has been shown to be sufficient for 
specification of cardiomyocyte fate in differentiating ES cells (Holtzinger et al., 
2010). This together with the fact that the myocardial differentiation program was 
not blocked in EBs, in which Trim33 was deleted after mesoderm-induction, 
suggests that the Nodal-Cripto signaling involved in ExEn specification is not 
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regulated by Trim33 (Kruithof-de Julio et al., 2011). Instead, our in vitro data 
imply that Trim33 deletion results in impaired VE differentiation.  
 
Trim33 is required in the embryo proper for appropriate cardiac 
development 
Our findings that a higher number of Trim33-deficient EBs show beating cell 
clusters and display upregulation of a cardiac failure marker Ankrd1 suggests 
that Trim33 plays either a direct role in appropriate myocardial differentiation or 
that Trim33 contributes to the cardiac differentiation via an indirect mechanism 
involving VE differentiation. However, deletion of Trim33 by using the Sox2Cre 
driver, which recombines specifically in the epiblast but not in ExEn (hence 
effectively does not recombine in the VE), resulted in cardiac defects, suggesting 
that Trim33 regulates early cardiac differentiation directly in the embryo proper. 
Strikingly, there were no gross cardiac phenotypes in the mesendoderm-specific 
Trim33FF:TCre mutants. Sox2Cre has been shown to recombine at early epiblast 
stage prior to E5.75 (Chu et al., 2004), while strong TCre-induced recombination 
can be detected in the primitive streak and the lateral mesodermal wings at the 
mid-streak stage (E7.5) (Kumar et al., 2008). Our studies on EBs imply that the 
Trim33 protein is remarkably stable, which may contribute to the milder 
phenotypes we see in Trim33FF:TCre+ mutants. Collectively, these results 
suggest that Trim33 is required at the time when the mesodermal multipotent 
progenitor cells commit to the cardiac lineage, and that it may play a minor or no 
role in more committed cell lineages. 
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Trim33, lipid metabolism and morphogen signaling 
Trim33FF:Sox2Cre mutants show low-penetrant defects in the neural  tube 
closure (exencephaly) and atrial septation; the phenotypes that can be caused by 
deficient hedgehog (Hh) signaling (Hoffmann et al., 2009; Murdoch and Copp, 
2010). Cholesterol modification of Hh ligands is required for proper Hh signaling, 
and consequently the mouse mutants deficient in specific apolipoproteins and 
lipoprotein receptors, e.g., ApoB and Megalin show phenotypes similar to those 
seen in Hh pathway mutants (Farese et al., 1995; Willnow et al., 1996). While VE 
is the main site of apolipoprotein synthesis and function in midgestation embryos, 
the key lipid transporter Mttp is also expressed in the embryo proper already at 
E8.5 (Figure 4.13 A). Interestingly, Mttp expression was downregulated in 
epiblast-specific Trim33 mutants (Figure 4.13 A), which could contribute to 
changes in lipid metabolism resulting in exencephaly and atrial septal defects we 
detect with low penetrance.  
 
Trim33 regulates TGF-β signaling during cardiac development 
Although Trim33 has been implicated in many biological processes, our finding 
that Smad4 haploinsufficiency partially rescues the lethal phenotype of 
Trim33FF:Sox2Cre+ mutants strongly suggests that in this context Trim33 
suppresses TGF-β superfamily signaling. It has been suggested that TGF-β 
signaling plays a bimodal stage-specific role in cardiac development in vitro (Cai 
et al., 2012; Kitamura et al., 2007). According to this model Smad2 would first be 
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activated by Nodal/Cripto to induce mesoderm formation in mES cells between 
days 3-5 of differentiation, then after being inhibited from days 5 to day 7, Smad2 
would again be activated by TGF-β/Activin to suppress cardiomyogenesis 
(Kitamura et al., 2007). Paradoxically, a higher number of beating clusters in 
Trim33-deficient EBs suggests that TGF-β signaling is down-regulated in mutants 
during the phase in which it suppresses cardiomyogenesis. This is consistent 
with our biochemical data showing that Smad2 activation is less in Trim33-
deficient EBs (Figure 4.15). 
Our data imply that failure to attenuate Smad4-dependent TGF-β signaling in 
epiblast-specific Trim33 mutants during the narrow but critical time window in late 
mesoderm induction ultimately results in sustained reduction in TGF-β 
superfamily signaling. Among other changes, expression levels of the key 
cardiac transcription factors Tbx5 and Isl1 were affected in the developing heart 
followed by elevated expression of cardiac failure marker Ankrd1, which can be 
detected both in EBs in vitro and epiblast-specific Trim33 mutants in vivo. Those 
rare epiblast-specific Trim33 mutants that survive beyond E15 precipitate 
progressive cardiac failure resulting in hypoxia in craniofacial tissues (Figure 
4.10). Hypoxia during facial morphogenesis has been shown to result in cleft 
palate (Azarbayjani and Danielsson, 2001; Johnston and Bronsky, 1995). 
Previous work by our group demonstrates that abrogation of Trim33 in any of the 
cell types contributing to the palate, i.e., ectoderm (K14Cre), neural crest 
(Wnt1Cre) and endothelium (Tie2Cre), does not result in palatal phenotypes 
(Lane et al., 2015) and data not shown). Therefore it is likely that the palate 
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phenotype we see among epiblast-specific Trim33 mutants that survive beyond 
E15 is secondary to the cardiac defects and associated hypoxia in craniofacial 
tissues.
 
 
Figure 4.15. Conceptual model illustrating regulation of TGF-β superfamily signaling by 
Trim33 in the precardiac mesoderm. 
 
Implications for common congenital birth defects 
 
Our current data contribute to the bimodal stage-specific model proposed by (Cai 
et al., 2012; Kitamura et al., 2007). Specifically, we show that Trim33 attenuates 
to first wave of Tgfβ superfamily signaling. The loss of Trim33 likely results in 
prolonged/abnormally high pSmad2-Smad4 -mediated signaling activity; which 
subsequently leads to sustained attenuation of baseline TGF-β signaling activity 
during early commitment of cardiac progenitors (Figure 4.15). Strikingly, mouse 
embryos deficient in Trim33 suffer from VSDs and cleft palate, which belong to 
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the most common congenital birth defects in humans. These data generate an 
exciting new paradigm arguing that the common congenital birth defects can be 
caused by inappropriate regulation of early signaling processes preceding the 
organ formation, e.g. cardiogenesis or palatogenesis.  	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CHAPTER 5 
Trim33 regulates the naïve pluripotency network in mouse  
embryonic stem cells 
 
Abstract 
Embryonic stem cells (ESCs) are an established model for investigating 
developmental processes, disease conditions, tissue regeneration as well as 
therapeutic targets. While biochemical mechanisms that maintain the non-
differentiated, naïve state of pluripotency in both mouse (m) ESCs and human (h) 
ESCs are well understood, transcriptional networks that prime ESCs to exit from 
pluripotency and initiate the first events of differentiation, and mechanisms that 
dismantle ground state pluripotency are poorly known. Here I report that mESCs 
deficient in Trim33 are indistinguishable from control cells when cultured under 
non-differentiating conditions. However, when induced to differentiate, they show 
pronounced morphological changes and display sustained up-regulation of key 
pluripotency factors e.g., Esrrb, Tfcp2l1, Klf5. My results suggest that Trim33 
regulates equilibrium between naïve pluripotency and reversible/transitional 
phases prior to achieving primed pluripotency and earliest lineage segregation 
events in differentiating mESCs. 
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Introduction 
Embryonic stem cells (ESCs) have been used to investigate developmental 
processes, disease conditions, tissue regeneration as well as therapeutic targets 
in vitro (Evans, 2011). Transcriptional networks underlying ground state 
pluripotency have been a subject of intense study in both mouse as well as  
human embryonic stem cells and used effectively for derivation of induced 
pluripotent cells (Gafni et al., 2013; Hanna et al., 2010; Posfai et al., 2014; 
Robinton and Daley, 2012). During the last 3 decades several key findings have 
contributed to the development of protocols that allow culture of non-
differentiated, naïve state mESCs and hESCs in vitro. Mouse ESCs are 
dependent on Leukemia Inhibitory Factor (LIF) and BMP signaling while hESCs 
require Fgf and Nodal/Activin signaling for successful propagation in culture in 
their pluripotent state (Besser, 2004; James et al., 2005; Martello and Smith, 
2014; Williams et al., 1988; Ying et al., 2003; Ying et al., 2008). Mouse ESCs can 
also be effectively maintained in undifferentiated state with specific small 
molecule inhibitors of ERK and the GSK3β kinase signaling (2i conditions) 
without LIF (Ying et al., 2008). The fact that ESCs require special, defined 
conditions for propagation in culture in ground state pluripotency and respond to 
external changes by rapidly defaulting to a differentiated fate suggests that naïve 
pluripotency is wired to collapse (Martello and Smith, 2014). However, 
transcriptional networks that prime ES cells to exit from pluripotency and 
mechanisms by which the ground state pluripotency is dismantled are currently 
poorly known (Martello and Smith, 2014). Here we demonstrate that Trim33, a 
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tumor suppressor and transcriptional regulator, is required for normal early 
mESC differentiation. Specifically, differentiating mESCs deficient in Trim33 fail 
to form morphologically normal appearing embryoid bodies (EBs) during the early 
phases of differentiation, and display sustained up-regulation of core pluripotency 
factors. Our results imply that Trim33 regulates the balance between the naïve 
pluripotency and transitional/primed phases in early differentiating mESCs.  
 
Results and Discussion 
mESC lines were established from mouse blastocysts that were homozygous for 
the floxed Trim33 allele and additionally carried the UbcCreERT2 transgene 
(Trim33FF:UbcCreERT2 ESCs).  When these cells were exposed to 4-
hydroxytamoxifen (4-OHT), sequences encoded by exons 2-4 were excised, and 
ESCs lacking the functional Trim33 gene (Trim33KO) were generated (Figure 
5.1). Trim33KO ESCs were indistinguishable from control cells when cultured 
under non-differentiating conditions in the presence of LIF+2i (Figure 5.1. A-D). 
They expressed the stem cell markers SSEA-1 (Figure 5.1. E-F), the key 
pluripotency factor Pou5f1 and showed characteristic ESC colony morphology 
identical to that of control mESCs. Trim33KO ESCs were propagated in culture 
over 20 days, corresponding to 6 passages without detectable morphological 
changes (Figure 5.1). 
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Figure 5.1. Trim33KO ESCs are indistinguishable from control ESCs under non-
differentiating culture conditions. (A-H) shows mESCs cultured with LIF+2i (A-D): Bright field 
images of control (A, B, 4-OHT-) and Trim33KO (C, D, 4-OHT+) Trim33FF:UbcCreERT2 ES cells 
showing characteristic ESC colony morphology. (E-H): Immunohistochemistry images for control 
(E, F) and Trim33KO cells (G, H), both expressing the SSEA and Pouf51 antigen. Scale bar (A-H) 
200µm. (I) shows schematic presentation of the targetedTrim33 locus. Arrows a, b, and c depict 
the primers used in the genotyping assay (F). F: #1 is Trim33FF:UbcCreERT2, 4-OHT- and #2 is 
Trim33FF:UbcCreERT2, 4-OHT+, other lanes are known controls. 
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Figure 5.2. Trim33KO EBs show distinct morphology and expression profile as compared to 
control and SB431542-treated EBs. (A-F) Representative images of EBs at day 5 (A-C) and 
day 9 (D-F) in differentiation. EBs were treated with 4-OHT (B, E) and SB431542 (C, F) at 24 
hours into differentiation culture. EBs in (B) have a flattened appearance and are shedding cells 
on periphery. Scale bars=1mm (G) mRNA expression by qRT-PCR for Trim33, pluripotency 
marker Pouf51, mesoderm marker Gsc and ectoderm marker Nes in corresponding EB samples 
as in A-F. 
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The critical role of TGF-β/Nodal signaling in mesendoderm induction is well-
established (Conlon et al., 1994). Moreover, previous studies have shown that 
the function of Trim33 as a chromatin reader is required for Nodal-triggered 
mesendoderm induction (Xi et al., 2011). To complement and expand these 
findings, we tested whether deletion of Trim33 and inactivation of TGF-β/Nodal 
type I receptors (by a chemical inhibitor SB431542 (Inman et al., 2002)) would 
result in identical outcomes. To this end, ESCs were cultured without LIF and 2i 
in the presence of Fetal Calf Serum (FCS), i.e., conditions that are permissive for 
ESCs to form EBs and differentiate. Under these culture conditions, control ESCs 
(4-OHT-) formed well-defined, cystic EBs (Figure 5. 2 A and D). In contrast, 
Trim33FFUbcCreERT2 ESCs treated with 4-OHT failed to form discernable EBs 
and showed a large amount of shedding cells on the surface of the EB  
(Figure 5.2 B); there were an insignificant number of clusters beyond day 5 
(Figure 5. 2 E). SB431542-treated cultures appeared to form differentiating EBs 
comparable to control cultures in earlier stages, however, beyond day 5 they lost 
the EB-like structure and assumed a flattened, amoeboid-like morphology. 
Clusters that survived remained attached to the low attachment dish used for the 
EB culture (Figure 5.2 F). 
Since the control EBs and those cultured in the presence of 4-OHT or 
SB431542 appeared all morphologically distinct, I analyzed expression levels of 
well-established germ layer and pluripotency markers by using qRT-PCR.  As 
expected, both SB431542-treated and 4-OHT-treated EBs failed to express 
mesendoderm markers Gsc and Foxa2 (Figure 5.2 G and data not shown), while 
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the ectoderm marker Nestin was normally expressed (Figure 5.2 G). However, 
the key pluripotency marker Pou5f1 was barely detectable in SB431542-treated 
cultures, while the 4-OHT+ Trim33KO cultures showed high levels of Pou5f1 
expression both 5 and 7 days after induction of differentiation (Figure 5.2.G). 
These data suggest that cells lacking Trim33 favor more primitive, closer-to-
ground state pluripotency, and thus the role of Trim33 during these first days of 
differentiation is not simply to regulate Nodal-induced mesendoderm formation.   
Characterization of Trim33KO EBs showed an increased number of 
apoptotic cells at day 3.5 when assayed for cleaved caspase-3 (Figure 5.3). 
However, the positively staining cells did not co-localize with peripherally 
shedding cells on the surface of the Trim33KO EBs.  A recent study showed that 
Trim33 deficiency correlates with enhanced sensitivity to DNA damage (Kulkarni 
et al., 2013).  To examine whether DNA damage would contribute to the 
Trim33KO EB phenotype, we stained both control and Trim33KO EBs for the DNA 
damage marker γH2AX (Figure 5.4). This assay revealed that in differentiating 
EBs there are no detectable differences in γH2AX staining between controls and 
Trim33 mutants suggesting that in this context Trim33 is not involved in a DNA 
damage response. 
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Figure 5.3. Trim33KO EBs show increased apoptosis at day 3.5 of differentiation. Cre 
induction at day 0 of differentiation. (A) Representative images of control and Trim33KO EBs at 
days 2, 2.5 and 3.5 in differentiation showing immunostaining for cleaved caspase3 (clcaspase3, 
green). To identify cell boundaries, the EBs were stained for F-actin (red, also highlighted  in 
single channel black and white day 3.5 images; lower right pictures). Nuclear staining with DAPI, 
blue. Scale bars, Day 2.0 and 2.5, 100µm; Day 3.5, 200µm (B) Quantification of per cent 
apoptotic cells. Error bars = +/- SEM. 
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Figure 5.4. Trim33KO EBs do not accumulate DNA double strand breaks. Representative 
images of control and Trim33KO EBs at days 2.5 showing immunostaining for γH2AX (green); the 
basement membrane was stained for laminin (red) Scale bars, 200µm. Nuclear staining with 
DAPI, blue). 
 
To better understand the role of Trim33 in initial phases of ESC differentiation, 
we performed genome-wide transcriptomic analyses using RNASeq on RNAs 
harvested from control 4-OHT- and 4-OHT+ differentiating mESCs 
(Trim33FF:UbcCreERT2) at day-2 and day-2.5 of differentiation (4-OHT induction at 
the initiation of differentiation). These assays returned several differentially 
expressed genes involved in ESC self-renewal, while only a few genes involved 
in ESC differentiation were differentially expressed (Figure 5.5). None of the 
differentially expressed genes were directly involved in apoptotic responses 
suggesting that the increased apoptosis detected in mutant EBs during the 4th 
day of differentiation is secondary to the earlier changes in cell differentiation. In 
addition to Trim33, only a few genes were down regulated (Figure 5.5). One of 
them was Rac1 (2-fold down at day 2), which has been implicated in EB survival 
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(He et al., 2010). Notably, within 48 hours of Trim33 transcriptional deletion, 
Stat3, Socs3, Klf factors, Tfcp2l1 and Esrrb were up regulated. The 
aforementioned Klf factors and Tfcp2l1, both of which are downstream targets of 
Stat3 (in effect downstream of LIF), have been validated as mediators of 
pluripotency (Gafni et al., 2013; Matsuda et al., 1999; Niwa et al., 1998; Qiu et 
al., 2015; Ware et al., 2014; Ye et al., 2013). While Stat3 activation downstream 
of LIF signaling plays a critical and well-characterized role in mESC renewal 
(Matsuda et al., 1999; Niwa et al., 1998), recent reports suggest that it could 
carry a similar function in naïve human stem cells as well (Gafni et al., 2013; 
Ware et al., 2014). Moreover, high Stat3 expression has been shown to be able 
to prime mouse epiblast stem cells towards a more naïve pluripotent state (van 
Oosten et al., 2012; Yang et al., 2010). Socs3, a well-known target of LIF-Stat3 
signaling, has been suggested to play an important regulatory role in ESC 
survival (Duval et al., 2000), while Tfcp2l1 is a common downstream mediator of 
both Stat3 and Wnt signaling pathways (Qiu et al., 2015; Ye et al., 2013). Esrrb, 
which has been known to be able to activate Pou5f1 and sustain ES cells in 
pluripotent state in the absence of LIF (Zhang et al., 2008), is concomitantly 
highly up regulated in Trim3KO EBs. Esrrb itself functions downstream of Gsk3 
inhibition (Martello et al., 2012). Its up regulation in Trim3KO cultures would 
therefore create a parallel circuitry maintaining pluripotency independent of the 
LIF-Stat3 pathway. Taken together, these data suggest that Trim33 actively 
regulates equilibrium between naïve pluripotency and reversibility/transitional 
phases before the earliest lineage segregation events in differentiating mESCs. 
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Figure 5.5. Several core pluripotency genes are upregulated in Trim33KO EBs.Log2fold 
change of selected targets from differentially expressed genes from RNA-Seq data at days 2 and 
2.5 in differentiation. N = 3 independent sample pairs of control and Trim33KO EBs. 
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Figure 5.6. A conceptual model of regulation of pluripotency network and exit from 
pluripotency by Trim33.  Trim33 regulates meta-states of pluripotency in vitro, in particular exit 
from pluripotency to the transitional or primed-for-differentiation phase. In the absence of Trim33, 
the equilibrium shifts toward predominance of a core transcriptional program that sensitizes 
progenitor cells towards inappropriately differentiated cell fates. 
 
Implications for developmental processes and cancer 
Trim33 has been shown to redundantly regulate differentiation of neural stem 
cells (Falk et al., 2014) and terminal differentiation of mammary epithelial cells 
(Hesling et al., 2013). In both contexts, Trim33 appears to control differentiation 
fates early on. In concordance, Trim33 has been shown to function as a tumor 
suppressor in different malignancies, such as chronic myelomonocytic leukemia, 
hepatocellular carcinoma and pancreatic ductal adenocarcinoma (Aucagne et al., 
2011; Herquel et al., 2011; Vincent et al., 2009). One of the salient features of 
malignant cancerous lesions is poor differentiation and amplification of 
transformed cell populations. Our current results suggest that Trim33-deficiency 
keeps stem cells in a naïve pluripotent state (or sensitizes progenitor cells 
Naïve state  
 
  
Transitional phase/ 
primed-for-differentiation  
Trim33 
Trim33 X!
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towards undifferentiated cell fates), which could also explain why cells that have 
defects in Trim33-regulated processes are insensitive to differentiation signals 
during pathological conditions, such as cancer. Our results suggest that Trim33 
controls the balance between stem/progenitor cell self-renewal and their ability to 
commit definitively to appropriate differentiation fates in a context dependent 
manner by actively regulating disassembly of the naïve pluripotency network 
(Figure 5.6).  
 
Experimental Procedures 
Ethics Statement 
This research was conducted in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes 
of Health. Experiments described are specifically approved by the University 
Committee on Use and Care of Animals at the University of Michigan-Ann Arbor 
(Protocol Number: PRO00005004). 
Establishment of embryonic stem cell lines and EB culture 
Mouse ES cells were derived from Trim33FF: UbcCreERT2 blastocysts as 
described in (Pieters et al., 2012); ESCs were passaged in serum-containing 
medium (Life Technologies, Cat. No. 16141-061), dissociating with TrypLE 
Express (Life Technologies, Cat. No. 12605-010) and maintained in serum 
replacement medium (Knock Out Serum Replacement Cat No. 10828-010, Life 
Technologies) in a base medium of 1:1 Knock Out Dulbecco’s Modified Eagle’s 
Medium and Ham’s F12. Trim33FF: UbcCreERT2 ESCs were maintained in feeder-
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free culture conditions in the presence of 2i+LIF (2i: PD0325901 (Stemgent) in 
final concentration of 0.4µM and CHIR99021 (Stemgent) in final concentration of 
3µM, LIF: (1000X) ESGRO (Millipore) ESG 1106) on 0.1% gelatin (Sigma, 
G1393) coated tissues culture plates. EB formation and differentiation were 
carried out per the ATCC protocol in 20% serum containing medium. Both the 
media for non-differentiating and differentiating conditions were supplemented by 
Glutamine (GlutaMAX-l (100X), Life Technologies, Cat. No. 35050-061), β-
mercaptoethanol (1000X, Life Technologies, Cat. No. 21985-023) and 
Penicillin/Streptomycin (Life Technologies, Cat. No.15140-122).  
4-hydroxytamoxifen (4-OHT) (Sigma Cat. No. T176) was added at 
intended and precise time points in a concentration of 1 µg per mL of medium. 
EB cultures were treated with SB431542 (Sigma) at concentration of 10µM, in 
parallel with 4-OHT treatments for equivalent duration of time.  
Real-time PCR 
Equivalent amounts/number of EBs were collected in 100-200 µL of commercially 
available (Qiagen) RLT buffer at intended time points. RNA was isolated using 
(Qiagen RNesy Mini Kit Cat. No 74104) and cDNA was synthesized using 
Omniscript RT(Qiagen Cat. No.205111) with standard methods. Taqman Assay 
reagents (Life Technoligies) were used for all targets except Actb, which was 
used to normalize expression levels. Universal Probe Library-based assays for 
Actb (Roche Applied Science) with gene-specific primer sequences generated by 
the manufacturer’s online algorithm and Taqman assay details are below. 30µl 
assays dispensed in TaqMan Universal PCR 2X master mix (Applied 
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Biosystems) with or without universal probe were quantified using Applied 
Biosystems ABI7300 PCR and ViiA7 detection systems and software. All Ct 
values were manually checked. cDNA was diluted where necessary to avoid Cts 
lower than 18.  
Taqman Assays # are provided in parenthesis: Gsc (Mm00650681_g1), Nes 
(Mm00450205_m1), Pouf51 (Mm00658129_gH), Trim33 (Mm01308695_m1) 
Actb: Forward Primer (tgacaggatgcagaaggaga), Reverse Primer      
(cgctcaggaggagcaatg), Universal Probe #106. 
RNA-Seq 
Equivalent amounts/number of EBs were collected at Day 7 in triplicate mutant-
control pairs, in 100-200 µL commercially available (Qiagen) RLT buffer. Total 
RNA was isolated using (Qiagen RNeasy Mini Kit Cat. No. 74104). mRNA and 
sequencing libraries were prepared by the University of Michigan DNA 
Sequencing Core and reads generated on Illumina HiSeq2000. After quality 
assessment per sample, single-end, 52 base pair reads were aligned to mm9 
(Mus musculus assembly July 2007) using STAR RNA Seq aligner (Dobin et al., 
2013). On average, input reads ranged between 35 million to 42 million across all 
samples, out of which approximately 80 per cent reads mapped uniquely. Read 
counts for differential expression were obtained using HTSeq program. 
Differential expression analyses were performed using the DESeq program in R 
Statistical Package. 
https://bioconductor.org/packages/3.3/bioc/vignettes/DESeq/inst/doc/DESeq.pdf.  
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Immunohistochemistry 
EBs were collected in sterile DBPS and fixed for 15 minutes in fresh 4% 
paraformaldehyde in PBS at RT.  Briefly, for cryo sections, EBs were washed in 
PBS, processed through sterile 10% sucrose in PBS, 7% gelatin (Sigma G6650, 
75 bloom) and 15% sucrose in PBS. EBs were embedded in fresh 7% gelatin: 
15% sucrose in PBS on ice, held on dry ice to store at −20 or −80 °C. 10µm cryo 
sections were cut and stored at −20 or −80°C. Antigen retrieval was not needed. 
Primary antibodies to SSEA (Developmental Studies Hybridoma Bank Cat.No. 
MC480), Pouf51 (C30A3) (Cell Signaling Cat. No. 2840), cleaved caspase3 (Asp 
175) (Cell Signaling Cat.No.9661), γH2AX (EMD Millipore Cat. No. DR1016) and 
laminin (Sigma Cat.No. L9393) were used according to manufacturer’s 
instructions. 	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CHAPTER 6 
 
Summary, conclusions and prospects 
 
Trim33 in cardiac differentiation 
Both mouse genetics and embryonic stem cell (ESC) differentiation systems 
have been widely used to dissect molecular mechanisms of disease. ESCs as 
well induced pluripotent stem cells (iPSCs) have also been used extensively to 
model regenerative mechanisms and to develop therapeutic targets in vitro. 
In this study, I used ES cell-based in vitro differentiation assays and tissue-
specific knockout mouse models to investigate the role of Trim33 in mouse 
development.  
 
I found that deletion of Trim33 in embryoid bodies after mesoderm induction 
results in morphological, functional and molecular changes in visceral endoderm 
and cardiac mesoderm in vitro. Visceral endoderm (VE) provides nutrients and 
instructive morphogen signals for appropriate cell fate and patterning decisions 
(Bielinska et al., 1999). The anterior visceral endoderm (AVE) constitutes a 
distinct population of ExEn cells and plays critical role in positioning of the head 
and heart (Madabhushi and Lacy, 2011). In my experimental conditions (Chapter 
4), Trim33-deficient EBs are viable and form beating clusters. However, at later 
stages the mutant EBs show less-expanded cystic appearance and several VE 
associated genes are dramatically down regulated in Trim33-deficient EBs even 
before the morphological differences are obvious (Chapter 4). 
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My findings that a higher number of Trim33-deficient EBs show beating cell 
clusters and display up regulation of a cardiac failure marker Ankrd1 suggests 
that Trim33 plays either a direct role in appropriate myocardial differentiation or 
that Trim33 contributes to the cardiac differentiation via an indirect mechanism 
involving VE differentiation. Trim33 deletion in the embryo proper (i.e. epiblast) 
using the Sox2Cre driver results in embryonic lethality around embryonic day (E) 
13 in mice, VSD and cardiac failure as a primary phenotype. However, the 
Sox2Cre driver specifically recombines and deletes Trim33 in the epiblast but not 
in the VE, suggesting that Trim33 regulates early cardiac differentiation directly in 
the embryo proper. Mesendoderm-specific deletion of Trim33 using the TCre 
driver did not result in gross cardiac phenotypes. Sox2Cre has been shown to 
recombine at early epiblast stage prior to E5.75 (Chu et al., 2004), while strong 
TCre-induced recombination can be detected in the primitive streak and the 
lateral mesodermal wings at the mid-streak stage (E7.5) (Kumar et al., 2008). 
Collectively, these results suggest that Trim33 is required at the time when the 
mesodermal multipotent progenitor cells commit to the cardiac lineage. In vivo, 
posterior epiblast cells comprise mesoderm precursors that also include cardiac 
progenitors. These presumptive cardiac progenitors assume cardiac identity in 
part during their ingression from the primitive streak and simultaneously retain 
lineage potency of the epiblast i.e. cell fates are plastic (Tam et al., 1997). In 
addition, cardiac-specific deletion of Trim33 using the Nkx2_5Cre driver did not 
result in any abnormalities in the heart, Trim33FF:Nkx2_5Cre+ mutants are 
viable, fertile and live normal life spans. Taken together, Trim33 plays a non-
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redundant role between the onset of gastrulation and cardiac specification. 
Whether the phenotypic outcomes in vivo are cell autonomous or not remains to 
be shown. As discussed earlier, the AVE plays important roles in positioning of 
the head and heart. In addition, the definitive endoderm, which is arises in 
concert with mesoderm as cells ingress through the streak (Lewis and Tam, 
2006) also influences cardiac patterning (Sugi and Lough, 1994; Uosaki et al., 
2012; Van Vliet et al., 2012).  Although the endoderm-derived molecules that 
specifically signal to induce normal cardiac patterning are not fully understood, 
TGF-β signaling components among other signaling pathways are strong 
candidates implicated in such a role (Lough and Sugi, 2000; Sugi and Lough, 
1995; Van Vliet et al., 2012). Concordantly, Trim33 as a regulator of TGF-β 
signaling would be a logical candidate and my data provide circumstantial 
evidence coinciding with the timing of the aforementioned inductive effects by 
definitive endoderm and cardiac differentiation in vivo. The strongest evidence 
that Trim33 regulates TGF-β signaling in cardiac morphogenesis is provided by 
the partial rescue of the epiblast-specific Trim33 lethal phenotype by Smad4 
haploinsufficiency.  
 A biphasic stage-specific role of Smad2 activity downstream of Activin/Nodal 
and TGF-β signaling in cardiac development has been demonstrated in vitro. In 
this model, Activin/Nodal signals are positive regulators for the early 
differentiation of mESCs in the initial phase while TGF-β signals play inhibitory 
roles in cardiac differentiation in the latter phase.  (Cai et al., 2012; Kitamura et 
al., 2007). The higher number of beating clusters in Trim33-deficient EBs 
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suggests that TGF-β signaling is down regulated in mutants during the phase in 
which it suppresses cardiomyogenesis and consistent with this observation, day 
7 Trim33-deficient EBs show reduction in Smad4 and pSmad2 protein levels in 
vitro. 
 Apart from the cardiac phenotype, all epiblast-specific Trim33 mutants that 
were occasionally retrieved in stages E17-18 showed cleft palate defect, 
evidently a secondary hypoxic phenotype from ensuing cardiac failure.  
 Other less penetrant phenotypes observed in epiblast-specific Trim33 
mutants, in particular those associated with down regulation of Mttp and 
lipoprotein-associated mechanisms are intriguing given the similarity in timing of 
embryonic lethality.  
 
Trim33 in early mES cell differentiation 
Results from Trim33KO ES cells in differentiation (Chapter 5) highlights the role of 
Trim33 in maintaining the equilibrium between meta-states of pluripotency. 
Specifically, on a continuum of pluripotency to the earliest differentiation event, 
Trim33KO ES cells favor a more primitive fate; up regulating several core 
pluripotency factors including some that are critical in maintaining mESCs in 
culture (Chapter 5). Whether the mES cell on the periphery of pluripotency 
reciprocally interprets Trim33 deficiency as an instruction to pause impending 
differentiation cannot be concluded from transcriptional analyses alone. It does 
generate the next hypothesis and the Trim33KO ES cell differentiation data are 
therefore valuable from a stem cell biology aspect. 
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Conclusions 
Collectively, Trim33 regulates extra embryonic endoderm development in vitro 
and Trim33 is required in the embryo proper for normal cardiac development. 
Trim33 regulates TGF-β signaling in cardiac differentiation. In addition, Trim33 is 
required for exit of mES cells from pluripotent phase towards a primed-for-
differentiation phase. Thus, from two independent contexts, the emerging 
paradigm is that Trim33 plays a non-redundant role in regulating progenitor cell 
fate within the window of plasticity and that in more committed lineages, Trim33 
is dispensable. 
 
Observations from the scope of in vitro and in vivo experimental methods 
Within my EB experimental set up, mES cells were allowed to undergo native 
differentiation in suspension culture and Trim33 was deleted post mesendoderm 
induction at day 4 and EBs were harvested at day 7. As expected, none of the 
mesendoderm genes were differentially expressed. However, Trim33-deficient 
EBs clearly showed functional aberrancy in cardiomyocyte differentiation 
reflected by elevation of Ankrd1, which was recapitulated in vivo in epiblast-
specific Trim33 mutants along with prominent structural defects of VSD and thin 
compact myocardium and functionally, cardiac failure. The EBs thus successfully 
recapitulate early development of the embryo proper. It should be noted that the 
complexity of cell-cell interactions and timing of events in embryogenesis do not 
overlap perfectly with those in the EB in vitro although it is a practical and close 
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approximation. For instance, the described Trim33-deficient EBs do not have the 
equivalent of an epiblast-specific Trim33 deletion. Native differentiation of EBs 
captures in part processes implicit to the epiblast or embryo proper while 
simultaneously capturing processes that are counterparts of extra embryonic 
tissues; the VE-related findings in Trim33 deficient EBs meet the latter criteria. 
The in vivo data from relevant Trim33 conditional mutants described here are 
consistent and align with the extrapolations made from Trim33 deficient EBs. 
Taken together, both the in vitro and in vivo experimental models elucidate the 
complexity of the Trim33 mutant phenotype in what is a differentiation as well as 
patterning defect. 
  
Prospects 
Several independent aspects can be further investigated for the comprehensive 
understanding of the role of Trim33 in early embryogenesis. It will be interesting 
to further detail the role of Trim33 as a chromatin reader regulating the 
interactions between Smad2/3 and modified histones in the context of 
cardiomyocyte differentiation using techniques such as Chromatin 
Immunoprecitation with parallel sequencing (ChIP-Seq) (Morikawa et al., 2013; 
Postma et al., 2016; Robertson et al., 2007).Trim33-deficient EBs described here 
show down regulation of several VE-associated genes, which plausibly suggests 
a mechanism underlying the phenotype and early lethality observed in germline 
Trim33 mutants (Kim and Kaartinen, 2008). If the said hypothesis is true, deletion 
of Trim33 in a VE-specific manner using an appropriate Cre driver such as the 
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TtrCre (Kwon and Hadjantonakis, 2009) should phenocopy the Trim33 germline 
mutant phenotype. Given the similarity of timing of embryonic lethality in epiblast-
specific Trim33 mutants and Mttp mutants (Raabe et al., 1998) and down 
regulation of Mttp in epiblast-specific Trim33 mutants, it will be interesting to 
generate an allelic series of Trim33 and Mttp mutants and observe their 
phenotypes. Finally, with respect to precisely mapping cell types that contribute 
to the cardiac phenotype in epiblast-specific Trim33 mutants, a combination of 
genetic tools and advanced live imaging techniques (Chen et al., 2014; Liu and 
Keller, 2016) will be valuable in further detailing the role of Trim33 in cardiac 
morphogenesis. 
 
Significance 
The incidence of Congenital Heart Disease (CHD) is 1-2% of all live births and 
covers the entire spectrum of congenital heart defects (Hoffman and Kaplan, 
2002; van der Linde et al., 2011). Ventricular Septal Defects (VSDs) are the most 
common among all CHDs and the primary cause remains genetic ranging from 
chromosomal abnormalities, single gene mutations, epigenetic as well as 
environmental effects although sporadic VSDs are also known (Edwards and 
Gelb, 2016; Richards and Garg, 2010; Wolf and Basson, 2010; Yuan et al., 
2013). Most CHDs including VSD are multifactorial in etiology and occur either as 
isolated defects or as part of syndromes, often with craniofacial anomalies (Blue 
et al., 2012).  
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From the paradigm of the conclusions of this research, it is critical to understand 
fine-tuning and precise timing of mechanisms underlying congenital defects, in 
particular the importance of not excluding causes distant to the observed 
phenotype(s). This includes discriminating between global effects of genetic loss 
of function such as down regulation of Mttp observed in epiblast-specific Trim33 
mutants versus identifying lineage restricted phenotypes such as the VSD as well 
as the secondary hypoxic phenotype of cleft palate observed in the same mouse 
model. In the context of Trim33 as a regulator of TGF-β signaling, this work 
contributes and furthers the known repertoire of CHD resulting from disruption of 
TGF-β signaling dosage (Arthur and Bamforth, 2011). Decoding intertwining 
global and tissue/organ specific phenotypes will allow for better approaches in 
screening and identification of therapeutic targets for precise causative 
mechanisms underlying common human congenital defects. 
 
 
References 
 
Arthur, H.M., Bamforth, S.D., 2011. TGFbeta signaling and congenital heart 
disease: Insights from mouse studies. Birth Defects Res. A Clin. Mol. Teratol. 91, 
423-434. 
 
Bielinska, M., Narita, N., Wilson, D.B., 1999. Distinct roles for visceral endoderm 
during embryonic mouse development. Int J Dev Biol 43, 183-205. 
 
Blue, G.M., Kirk, E.P., Sholler, G.F., Harvey, R.P., Winlaw, D.S., 2012. 
Congenital heart disease: current knowledge about causes and inheritance. Med. 
J. Aust. 197, 155-159. 
 
Cai, W., Guzzo, R.M., Wei, K., Willems, E., Davidovics, H., Mercola, M., 2012. A 
Nodal-to-TGFbeta cascade exerts biphasic control over cardiopoiesis. Circ. Res. 
111, 876-881. 
 
	   104	  
Chen, B.C., Legant, W.R., Wang, K., Shao, L., Milkie, D.E., Davidson, M.W., 
Janetopoulos, C., Wu, X.S., Hammer, J.A., 3rd, Liu, Z., English, B.P., Mimori-
Kiyosue, Y., Romero, D.P., Ritter, A.T., Lippincott-Schwartz, J., Fritz-Laylin, L., 
Mullins, R.D., Mitchell, D.M., Bembenek, J.N., Reymann, A.C., Bohme, R., Grill, 
S.W., Wang, J.T., Seydoux, G., Tulu, U.S., Kiehart, D.P., Betzig, E., 2014. Lattice 
light-sheet microscopy: imaging molecules to embryos at high spatiotemporal 
resolution. Science 346, 1257998. 
 
Chu, G.C., Dunn, N.R., Anderson, D.C., Oxburgh, L., Robertson, E.J., 2004. 
Differential requirements for Smad4 in TGFbeta-dependent patterning of the 
early mouse embryo. Development 131, 3501-3512. 
 
Edwards, J.J., Gelb, B.D., 2016. Genetics of congenital heart disease. Curr. 
Opin. Cardiol. 
 
Hoffman, J.I., Kaplan, S., 2002. The incidence of congenital heart disease. J. 
Am. Coll. Cardiol. 39, 1890-1900. 
 
Kim, J., Kaartinen, V., 2008. Generation of mice with a conditional allele for 
Trim33. Genesis 46, 329-333. 
 
Kitamura, R., Takahashi, T., Nakajima, N., Isodono, K., Asada, S., Ueno, H., 
Ueyama, T., Yoshikawa, T., Matsubara, H., Oh, H., 2007. Stage-specific role of 
endogenous Smad2 activation in cardiomyogenesis of embryonic stem cells. Circ 
Res 101, 78-87. 
 
Kumar, A., Lualdi, M., Lewandoski, M., Kuehn, M.R., 2008. Broad mesodermal 
and endodermal deletion of Nodal at postgastrulation stages results solely in 
left/right axial defects. Dev Dyn 237, 3591-3601. 
 
Kwon, G.S., Hadjantonakis, A.K., 2009. Transthyretin mouse transgenes direct 
RFP expression or Cre-mediated recombination throughout the visceral 
endoderm. Genesis 47, 447-455. 
 
Lewis, S.L., Tam, P.P., 2006. Definitive endoderm of the mouse embryo: 
formation, cell fates, and morphogenetic function. Dev. Dyn. 235, 2315-2329. 
 
Liu, Z., Keller, P.J., 2016. Emerging Imaging and Genomic Tools for 
Developmental Systems Biology. Dev. Cell 36, 597-610. 
 
Lough, J., Sugi, Y., 2000. Endoderm and heart development. Dev. Dyn. 217, 
327-342. 
 
Madabhushi, M., Lacy, E., 2011. Anterior visceral endoderm directs ventral 
morphogenesis and placement of head and heart via BMP2 expression. Dev Cell 
21, 907-919. 
	   105	  
Morikawa, M., Koinuma, D., Miyazono, K., Heldin, C.H., 2013. Genome-wide 
mechanisms of Smad binding. Oncogene 32, 1609-1615. 
 
Postma, A.V., Bezzina, C.R., Christoffels, V.M., 2016. Genetics of congenital 
heart disease: the contribution of the noncoding regulatory genome. J. Hum. 
Genet. 61, 13-19. 
 
Raabe, M., Flynn, L.M., Zlot, C.H., Wong, J.S., Veniant, M.M., Hamilton, R.L., 
Young, S.G., 1998. Knockout of the abetalipoproteinemia gene in mice: reduced 
lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. 
Proc. Natl. Acad. Sci. U. S. A. 95, 8686-8691. 
 
Richards, A.A., Garg, V., 2010. Genetics of congenital heart disease. Curr. 
Cardiol. Rev. 6, 91-97. 
 
Robertson, G., Hirst, M., Bainbridge, M., Bilenky, M., Zhao, Y., Zeng, T., 
Euskirchen, G., Bernier, B., Varhol, R., Delaney, A., Thiessen, N., Griffith, O.L., 
He, A., Marra, M., Snyder, M., Jones, S., 2007. Genome-wide profiles of STAT1 
DNA association using chromatin immunoprecipitation and massively parallel 
sequencing. Nature methods 4, 651-657. 
 
Sugi, Y., Lough, J., 1994. Anterior endoderm is a specific effector of terminal 
cardiac myocyte differentiation of cells from the embryonic heart forming region. 
Dev. Dyn. 200, 155-162. 
 
Sugi, Y., Lough, J., 1995. Activin-A and FGF-2 mimic the inductive effects of 
anterior endoderm on terminal cardiac myogenesis in vitro. Dev. Biol. 168, 567-
574. 
 
Tam, P.P., Parameswaran, M., Kinder, S.J., Weinberger, R.P., 1997. The 
allocation of epiblast cells to the embryonic heart and other mesodermal 
lineages: the role of ingression and tissue movement during gastrulation. 
Development 124, 1631-1642. 
 
Uosaki, H., Andersen, P., Shenje, L.T., Fernandez, L., Christiansen, S.L., Kwon, 
C., 2012. Direct contact with endoderm-like cells efficiently induces cardiac 
progenitors from mouse and human pluripotent stem cells. PLoS One 7, e46413. 
 
van der Linde, D., Konings, E.E., Slager, M.A., Witsenburg, M., Helbing, W.A., 
Takkenberg, J.J., Roos-Hesselink, J.W., 2011. Birth prevalence of congenital 
heart disease worldwide: a systematic review and meta-analysis. J. Am. Coll. 
Cardiol. 58, 2241-2247. 
 
Van Vliet, P., Wu, S.M., Zaffran, S., Puceat, M., 2012. Early cardiac 
development: a view from stem cells to embryos. Cardiovasc. Res. 96, 352-362. 
	   106	  
Wolf, M., Basson, C.T., 2010. The molecular genetics of congenital heart 
disease: a review of recent developments. Curr. Opin. Cardiol. 25, 192-197. 
 
Yuan, S., Zaidi, S., Brueckner, M., 2013. Congenital heart disease: emerging 
themes linking genetics and development. Curr. Opin. Genet. Dev. 23, 352-359. 
 
	   107	  
 
APPENDIX 1 
 
Output list of differentially expressed genes in RNA-Sequencing data  
 
Column names as indicated. (padj = adjusted p value) 
 
 
Table A.1. Differentially expressed genes at day 7 in control and 
Trim33FF:UBCreERT2 (4-OHT+) embryoid bodies. Cre was induced at day 4 in 
differentiation culture. N= 2 independent sample pairs (Chapter 4). 
 
Gene Id  log2FoldChange  padj 
 Cdhr2  -Inf 0.002133191 
 Krt79 3.994900516 0.004073151 
 Nipal1 3.4968914 0.0000443 
 Prl3b1 3.047026522 0.000625295 
 Shisa3 2.15091521 0.019047286 
 Ankrd1 2.014463001 0.00084171 
 Nfxl1 1.243005403 0.000625295 
 Cd44 1.235540874 0.000342188 
 Scd1 0.99666188 0.012472549 
 Dusp4 0.953691444 0.019703088 
 Scd2 0.931683852 0.000841271 
 Cyp51 0.892550394 0.005913254 
 Il6st 0.85269803 0.029935889 
 Sqle 0.84279181 0.022036397 
 Ldlr 0.808181619 0.034221117 
 Tpi1 -0.747736027 0.033110325 
 Slc2a1 -0.752625189 0.0236023 
 Galk1 -0.773304278 0.049597367 
 Aldoa -0.851215013 0.004073151 
 Gpi1 -0.86714941 0.00660598 
 Ddit4 -0.868007681 0.014142097 
 Ldha -0.877594523 0.003202994 
 Egln1 -0.929101674 0.006339872 
 Pgk1 -0.995003146 0.0236023 
 Slc16a3 -1.007216709 0.000647973 
 Pfkl -1.061333572 0.000139558 
 Lgmn -1.109833043 0.000277474 
 Pdk1 -1.19881452 0.00006 
 Egln3 -1.219590481 0.003850968 
 Trim33 -1.221779639 0.001085018 
 Tmprss2 -1.224883891 0.005584933 
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 Slc2a3 -1.28941248 0.000000222 
 Ak4 -1.385472863 0.0000443 
 Cited1 -1.422925645 0.003672725 
 Pappa -1.42614138 0.013824788 
 Bnip3 -1.435735016 0.0000919 
 Gstm1 -1.507158753 0.019047286 
 Ctsc -1.554228405 0.000989765 
 Ano1 -1.597088494 0.019047286 
 Pdzk1 -1.602985985 0.027840759 
 Clic6 -1.672027398 0.020051197 
 Reep6 -1.723923757 0.000187476 
 Camkv -1.775138836 0.007446037 
 B4galnt2 -1.813206138 0.004727369 
 Sepp1 -1.91541629 0.0000935 
 Hkdc1 -1.922288786 0.001369785 
 Fgfr4 -1.977882434 0.049597367 
 Habp2 -1.986214932 0.032661808 
 Ctsh -2.008981963 4.94E-10 
 Gli1 -2.025765329 8.85E-08 
 Mttp -2.17955073 0.00000156 
 Dpp4 -2.190025705 0.005762538 
 Ttr -2.449391718 0.001906598 
 Hnf4a -2.472472179 0.017445548 
 2610528J11Rik -2.528230892 0.002171964 
 Klb -2.553091813 0.028146909 
 Fgb -2.579024037 0.000978705 
 Npl -2.59657454 0.00000117 
 Lgals2 -2.714073368 0.001836455 
 Abcc2 -2.840831294 0.002066163 
 
2810459M11Rik -2.900913359 0.012472549 
 Slc13a4 -3.020413127 1.8E-10 
 S100g -3.026267738 9.6E-09 
 Slc39a5 -3.083548834 0.013824788 
 Pla2g12b -3.223048157 0.001906598 
 Soat2 -3.310471541 0.000813961 
 Apoa2 -3.437208856 0.000978705 
 Cldn2 -3.471504863 0.000000177 
 Trf -3.608709594 1.01E-15 
 F2 -3.773771206 0.000424684 
 Muc13 -3.943504297 0.007605514 
 Serpinf2 -3.997991214 0.0000499 
 Creb3l3 -4.061423165 0.001296533 
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 Apoa1 -4.154425087 0.00000342 
 Amn -4.313600839 1E-24 
 Apob -4.323436687 0.0000067 
 Cubn -4.749035918 3.19E-46 
 Afp -4.857191998 1.83E-10 
 Fga -4.934903394 0.02099508 
 Spp2 -5.322511087 0.000005 
 Apoa4 -5.429069677 0.00000096 
 Aldob -5.507023145 5.94E-11 
 Slc2a2 -5.703781631 0.000978705 
 Apoc2 -6.12733823 4.29E-41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   110	  
 
 
Table A. 2. Differentially expressed genes at day 2 in control and 
Trim33FF:UBCreERT2 (4-OHT+) embryoid bodies. Cre was induced at day 0 in 
differentiation culture. N= 3 independent sample pairs. A threshold of 0.5 in the  
log2FoldChange was used to include differentially expressed genes in this table. 
 
Gene	  Id	  
	  
	  
log2FoldChange	  
	  
Padj	  
	  
	  Mir377	   2.258006014	   0.031442616	  
	  Creb5	   2.020352456	   0.028342324	  
	  Fgfbp1	   1.999159881	   1.24E-­‐15	  
	  Slitrk3	   1.838329547	   0.016942864	  
	  Kctd19	   1.812067287	   0.004125777	  
	  Socs3	   1.765805929	   0.01593901	  
	  Cacna1e	   1.736254001	   0.045494784	  
	  Dusp8	   1.732085895	   7.90E-­‐05	  
	  Ahnak	   1.662613764	   0.01299176	  
	  Ctrb1	   1.65588798	   0.039090641	  
	  Ctgf	   1.583495846	   6.08E-­‐09	  
	  Irak3	   1.546580951	   0.010055033	  
	  Thsd7a	   1.528926352	   1.51E-­‐05	  
	  
1700061G19Rik	   1.526764205	   0.000523912	  
	  Rsph6a	   1.492009043	   0.044342729	  
	  Pdzrn4	   1.403049848	   1.13E-­‐05	  
	  Mme	   1.392074373	   4.17E-­‐08	  
	  Klhdc7a	   1.385200645	   0.015461789	  
	  Klf5	   1.370987078	   0.013050111	  
	  
E330020D12Rik	   1.363978676	   0.013050111	  
	  Tfap2c	   1.361777532	   0.003953708	  
	  P2rx7	   1.356557819	   0.000925968	  
	  Bcl3	   1.346259717	   0.00750789	  
	  Rasgrf2	   1.344678207	   0.038004671	  
	  Ccdc141	   1.331394119	   0.006601896	  
	  Ccdc85a	   1.289748522	   1.84E-­‐11	  
	  Sstr5	   1.267906908	   0.000285193	  
	  Cyb5r2	   1.244766224	   0.019362732	  
	  Tgfbr2	   1.241732396	   0.04393892	  
	  Cyr61	   1.241690732	   1.02E-­‐11	  
	  Map3k8	   1.226611648	   0.022273279	  
	  Abca8b	   1.221413193	   0.008958065	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  Esrrb	   1.195277986	   0.00012266	  
	  Arid5b	   1.194030156	   0.020356107	  
	  Lats2	   1.18813035	   0.000107015	  
	  Tfcp2l1	   1.172393244	   0.00113212	  
	  Trim61	   1.170559911	   0.035556167	  
	  Prex2	   1.16797677	   0.000164204	  
	  Shank1	   1.12375529	   0.015277611	  
	  Sox8	   1.117741527	   0.013653199	  
	  S100a11	   1.105622465	   0.011556456	  
	  Lamc2	   1.092276751	   0.020811885	  
	  Fmn2	   1.08742535	   7.32E-­‐06	  
	  Egfr	   1.083207935	   0.000856005	  
	  Fam83h	   1.06810464	   0.00244242	  
	  Chst1	   1.064329372	   1.84E-­‐15	  
	  Scrn1	   1.037812358	   6.84E-­‐06	  
	  Pdgfa	   1.034372738	   0.041122826	  
	  Stat3	   1.032348343	   3.08E-­‐10	  
	  Ano3	   1.0209393	   0.020900836	  
	  Nrip3	   1.016738677	   0.004540785	  
	  Diap2	   1.006366602	   8.24E-­‐07	  
	  Apela	   1.003420318	   2.47E-­‐15	  
	  Pclo	   0.997807035	   0.000815197	  
	  Neb	   0.992190282	   0.00093445	  
	  Csdc2	   0.988961203	   0.016188924	  
	  Tdh	   0.979167438	   0.000573214	  
	  Jun	   0.951661986	   5.97E-­‐05	  
	  Bmp7	   0.949778066	   0.016188924	  
	  Perp	   0.944117969	   0.000140176	  
	  Ddx58	   0.943958876	   7.82E-­‐06	  
	  Plk2	   0.941499904	   0.002032867	  
	  Sned1	   0.940864578	   0.001801624	  
	  Tbx3	   0.936950672	   0.020811885	  
	  Adrb3	   0.934752906	   0.000595851	  
	  Inpp5d	   0.927105162	   0.001302245	  
	  Lpar6	   0.926063366	   8.29E-­‐11	  
	  Neat1	   0.922352734	   0.010229192	  
	  
1700030C10Rik	   0.918427609	   0.009395207	  
	  Loxl1	   0.916617042	   0.040827362	  
	  Vwf	   0.91196589	   0.023176252	  
	  Slc12a8	   0.90837773	   0.028935728	  
	  Chrd	   0.906951436	   0.00076802	  
	  Rreb1	   0.897584182	   2.67E-­‐07	  
	  Ppfibp2	   0.894636931	   2.41E-­‐05	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  Plxnc1	   0.890644851	   0.043207506	  
	  Fam129a	   0.882260361	   2.43E-­‐05	  
	  Chrnb1	   0.87430884	   0.047245655	  
	  Shisa6	   0.866336213	   9.98E-­‐05	  
	  Icam1	   0.857818993	   0.027337927	  
	  Pdk4	   0.856728271	   0.002545057	  
	  Vwa5a	   0.849979956	   1.07E-­‐08	  
	  Dll1	   0.848537189	   5.22E-­‐09	  
	  Zhx1	   0.841376303	   0.01502115	  
	  Acox3	   0.83864258	   0.001302245	  
	  Aldh1l1	   0.834303664	   0.036056074	  
	  
C330046G13Rik	   0.828502097	   0.025034798	  
	  Dscaml1	   0.823691677	   0.040656833	  
	  Tpd52l1	   0.822514569	   2.88E-­‐08	  
	  Clvs2	   0.820553081	   0.008593968	  
	  Sh3tc1	   0.813874023	   0.012301207	  
	  Ap3b2	   0.811474907	   6.21E-­‐08	  
	  Gna15	   0.809224875	   0.001302245	  
	  Mmrn2	   0.80709085	   0.014264504	  
	  Apobec1	   0.805703491	   0.023251994	  
	  Slco4a1	   0.805413939	   0.002694	  
	  Frem2	   0.799679431	   0.00266818	  
	  Serping1	   0.796585481	   0.004437604	  
	  Rusc2	   0.792568967	   0.012344075	  
	  Nab2	   0.791135505	   0.005621243	  
	  Cyp51	   0.772716957	   1.28E-­‐18	  
	  Pwwp2b	   0.769847561	   0.001013909	  
	  Dusp10	   0.769163865	   0.034890405	  
	  Msmo1	   0.755164648	   1.19E-­‐16	  
	  Renbp	   0.752250328	   1.20E-­‐09	  
	  Zmat4	   0.750583624	   0.015397528	  
	  E030030I06Rik	   0.749630243	   0.023422419	  
	  Slc4a11	   0.748007142	   0.002260379	  
	  Sat1	   0.742525431	   9.92E-­‐05	  
	  Cd55	   0.737000103	   0.04128065	  
	  Artn	   0.734588924	   0.026222107	  
	  Ldlr	   0.734317278	   2.00E-­‐16	  
	  Tspan2	   0.726202494	   0.002545057	  
	  Cdkn1a	   0.726022089	   3.54E-­‐06	  
	  Patl2	   0.723801985	   0.047022566	  
	  Cdh2	   0.721801708	   0.002130789	  
	  Slc17a9	   0.719799717	   0.013922037	  
	  Star	   0.717603995	   0.023422419	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  Etnk1	   0.710049184	   0.000250712	  
	  Cpeb2	   0.7081141	   0.002004899	  
	  Sh2d3c	   0.70329578	   0.004328251	  
	  Scn1b	   0.701846674	   0.018657452	  
	  Plce1	   0.701826442	   0.012744548	  
	  Fbxo15	   0.701648918	   0.002590633	  
	  Srcrb4d	   0.700664133	   0.022344077	  
	  Fry	   0.699713961	   0.029492716	  
	  Tex19.1	   0.696767197	   0.005128945	  
	  Frmd4b	   0.696331683	   0.016185377	  
	  Btg2	   0.694692248	   3.08E-­‐10	  
	  Olig1	   0.693549145	   0.00094358	  
	  Trim56	   0.687163347	   0.013141869	  
	  Bambi	   0.687018657	   0.000367737	  
	  Mpv17l	   0.675352307	   4.21E-­‐05	  
	  Plagl1	   0.673588354	   0.009395207	  
	  Rap2b	   0.671720363	   0.000922718	  
	  Plekhm1	   0.670884639	   0.000117367	  
	  Sdc4	   0.668858822	   1.01E-­‐11	  
	  Fah	   0.663811252	   0.028342324	  
	  Mcam	   0.663048799	   0.000228003	  
	  Efr3b	   0.662621704	   2.01E-­‐06	  
	  Klf6	   0.661770757	   6.63E-­‐11	  
	  Trp53inp1	   0.65720006	   2.69E-­‐09	  
	  Tlr2	   0.650966281	   0.012626124	  
	  Fam212b	   0.647322364	   0.041122826	  
	  Dsg2	   0.64376608	   2.14E-­‐06	  
	  Tek	   0.643145689	   0.0130686	  
	  Il3ra	   0.640067792	   0.046429425	  
	  Fbxl16	   0.638544807	   0.041122826	  
	  Tmem47	   0.6375625	   1.64E-­‐07	  
	  Bach2	   0.63420271	   0.017188405	  
	  Lama3	   0.633470938	   0.001608618	  
	  Hmgcr	   0.631299514	   1.26E-­‐13	  
	  Cflar	   0.628773352	   0.035556167	  
	  Aacs	   0.628371261	   7.26E-­‐07	  
	  Relb	   0.627032898	   0.020811885	  
	  Colec12	   0.623850568	   0.000432108	  
	  Ptpn14	   0.623689642	   0.000369308	  
	  Nr4a1	   0.623216881	   0.000359023	  
	  S100a10	   0.622168686	   0.001409935	  
	  Eng	   0.620849685	   1.18E-­‐06	  
	  Sqle	   0.620786569	   3.17E-­‐12	  
	  Slc27a2	   0.620725522	   0.005684583	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  Thbs2	   0.612970748	   0.04341116	  
	  Mdm2	   0.606862221	   0.00015132	  
	  Gpr153	   0.600585102	   0.022428415	  
	  Ppm1k	   0.59831043	   0.043911349	  
	  Lamb2	   0.59511478	   0.000628038	  
	  Slc4a2	   0.592592021	   0.000107015	  
	  Insig1	   0.589580639	   0.001424673	  
	  Rfx2	   0.58910845	   0.048941643	  
	  Slc23a1	   0.588733839	   0.00230334	  
	  Fut9	   0.586878846	   0.000190657	  
	  Ryr3	   0.584907461	   0.008677159	  
	  Trap1a	   0.58390147	   0.000716408	  
	  
4930483K19Rik	   0.583325587	   0.012176364	  
	  Idh1	   0.583056884	   6.55E-­‐09	  
	  Unc13a	   0.581971029	   0.023017874	  
	  Hivep2	   0.58040254	   0.018370838	  
	  Cers4	   0.577861497	   0.005943364	  
	  Large	   0.573944004	   0.001144302	  
	  Dsp	   0.572640824	   0.00626634	  
	  Pmm1	   0.571259759	   5.84E-­‐06	  
	  Commd3	   0.566486342	   0.000741653	  
	  Gucy1a2	   0.555587362	   0.020356107	  
	  Triml1	   0.555394424	   0.041635419	  
	  Cpt1a	   0.546996395	   0.002694	  
	  Slc38a2	   0.546110257	   0.038842999	  
	  
D630023F18Rik	   0.545761804	   0.020811885	  
	  Rbm20	   0.544061124	   0.020811885	  
	  Igdcc4	   0.543182838	   0.006856887	  
	  Habp4	   0.542605694	   0.029492716	  
	  Zfp36l1	   0.540958644	   0.012311663	  
	  Prkx	   0.540193289	   0.023901764	  
	  Sh3pxd2a	   0.534216589	   0.032416068	  
	  Gli1	   0.532829693	   0.002891529	  
	  Parp4	   0.530225219	   0.027946367	  
	  Dcxr	   0.530195977	   0.003181556	  
	  Agrn	   0.524331966	   4.44E-­‐08	  
	  Syt9	   0.52345954	   0.000317847	  
	  Cdc42ep5	   0.522194126	   0.003659795	  
	  Zbtb10	   0.521852093	   0.007838324	  
	  Map3k9	   0.521190824	   0.001388762	  
	  Trim11	   0.520175609	   0.001719853	  
	  C77080	   0.519805205	   0.010216508	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  Il6st	   0.519383432	   0.000140176	  
	  Lefty1	   0.51859976	   3.70E-­‐06	  
	  Ajuba	   0.518012355	   0.000270476	  
	  Kcnh3	   0.51725818	   0.020811885	  
	  Gcnt2	   0.515752802	   0.000943776	  
	  Arid3a	   0.515703396	   0.022428415	  
	  Lnpep	   0.515052179	   0.016942864	  
	  Gprc5c	   0.513889608	   0.012344393	  
	  Mbnl2	   0.512894041	   4.77E-­‐05	  
	  Amotl2	   0.511565657	   4.71E-­‐07	  
	  Zcchc24	   0.511098337	   0.003518386	  
	  Atp1a3	   -­‐0.506504182	   0.002500133	  
	  Srl	   -­‐0.514290872	   0.000250712	  
	  
2810417H13Rik	   -­‐0.524526124	   3.42E-­‐05	  
	  Tnnt1	   -­‐0.531282851	   0.0170436	  
	  Arl4d	   -­‐0.53847818	   0.001409935	  
	  Ccnd1	   -­‐0.545020762	   0.007083928	  
	  Ccne2	   -­‐0.545681111	   0.005004541	  
	  Sgk1	   -­‐0.547934447	   5.16E-­‐09	  
	  Aif1l	   -­‐0.555707515	   0.002611517	  
	  Prickle1	   -­‐0.570869614	   0.020787015	  
	  Crym	   -­‐0.571741039	   0.021402848	  
	  Mns1	   -­‐0.57653028	   0.000750046	  
	  Pde2a	   -­‐0.592405029	   0.000628038	  
	  Trim46	   -­‐0.593476491	   0.02215252	  
	  Ccdc40	   -­‐0.595706035	   0.002260379	  
	  LOC100503496	   -­‐0.598703172	   0.032967957	  
	  Lmo2	   -­‐0.605559076	   0.049150132	  
	  Tdrd1	   -­‐0.623006087	   0.02172162	  
	  Tpt1	   -­‐0.645103025	   0.000815197	  
	  Slc16a6	   -­‐0.654921884	   0.000100324	  
	  Ntrk2	   -­‐0.665315464	   0.00191656	  
	  Stox2	   -­‐0.671249703	   7.43E-­‐05	  
	  Plac8	   -­‐0.711020652	   0.001645116	  
	  Fgf15	   -­‐0.715201062	   5.97E-­‐05	  
	  Prr19	   -­‐0.71979047	   0.001753224	  
	  Pla2g1b	   -­‐0.721261475	   6.06E-­‐06	  
	  Enpp2	   -­‐0.733409016	   0.000544805	  
	  Myl9	   -­‐0.773280859	   0.000943776	  
	  Psors1c2	   -­‐0.787829456	   0.020307352	  
	  Nrcam	   -­‐0.81891483	   0.010147349	  
	  Nlgn3	   -­‐0.879340594	   0.009820923	  
	  Hlf	   -­‐0.894493928	   0.025718165	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  Rac1	   -­‐1.018275145	   1.16E-­‐28	  
	  Gdpd1	   -­‐1.046965159	   0.012902938	  
	  Trim33	   -­‐2.037457292	   6.50E-­‐119	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Table A. 3. Differentially expressed genes at day 2.5 in control and 
Trim33FF:UBCreERT2 (4-OHT+) embryoid bodies. Cre was induced at day 0 in 
differentiation culture. N= 3 independent sample pairs. A threshold of 2 in the  
log2FoldChange was used to include differentially expressed genes in this table. 
 
Id	  
	  
	  log2FoldChange	  
	  
	  Padj	  
	  
	  Msln	   	  Inf	   6.63E-­‐07	  
	  Smok4a	   3.806525662	   9.14E-­‐09	  
	  Cacna1e	   3.711899487	   3.19E-­‐05	  
	  Sh3rf2	   3.51937051	   3.10E-­‐09	  
	  E330020D12Rik	   3.353313111	   1.30E-­‐10	  
	  Lgals3	   3.309490055	   5.16E-­‐39	  
	  Sim2	   3.146621736	   0.000810748	  
	  P2rx7	   3.140584496	   2.47E-­‐14	  
	  Ms4a10	   3.125133569	   1.64E-­‐08	  
	  Ahnak	   3.113684398	   2.13E-­‐16	  
	  Aox3	   3.111070825	   0.000361309	  
	  Sox8	   3.084415001	   4.74E-­‐16	  
	  Fgfbp1	   3.05458284	   7.14E-­‐84	  
	  A730082K24Rik	   3.0068022	   7.06E-­‐06	  
	  1700061G19Rik	   2.991691796	   1.54E-­‐18	  
	  Tlr5	   2.975935494	   0.000373971	  
	  Ebf2	   2.941305605	   0.000678282	  
	  Gm17019	   2.815398046	   0.000957665	  
	  Rapgef4	   2.791762118	   0.001396859	  
	  Sstr5	   2.782287102	   1.96E-­‐40	  
	  Gm10863	   2.687164148	   0.001010824	  
	  Itga8	   2.676234632	   5.78E-­‐12	  
	  Anxa8	   2.575615552	   1.77E-­‐30	  
	  Pcdhgb8	   2.565688682	   0.000439818	  
	  Clec10a	   2.560928364	   0.000308382	  
	  Anxa1	   2.550036936	   3.17E-­‐06	  
	  2700054A10Rik	   2.53920818	   3.48E-­‐25	  
	  C130021I20Rik	   2.532292581	   1.05E-­‐06	  
	  Slc9a9	   2.523065091	   0.000784979	  
	  Slfn2	   2.507651258	   0.000667761	  
	  A730036I17Rik	   2.501488952	   0.000199983	  
	  Ctrb1	   2.498473459	   7.06E-­‐08	  
	  Tspan32	   2.497249474	   7.94E-­‐07	  
	  Slfn3	   2.488455617	   0.008975749	  
	  Mgst2	   2.485411302	   0.00026834	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  Ccdc141	   2.479711522	   4.33E-­‐09	  
	  Irak3	   2.474308505	   4.46E-­‐22	  
	  Scg2	   2.451860136	   0.009218866	  
	  3830417A13Rik	   2.451408867	   0.004102275	  
	  Erv3	   2.441121901	   1.11E-­‐07	  
	  Th	   2.43828259	   0.00843696	  
	  Efhb	   2.406921821	   4.48E-­‐06	  
	  Dll1	   2.381565436	   2.86E-­‐10	  
	  Mir8091	   2.380410031	   0.007049365	  
	  Creb5	   2.376043841	   1.36E-­‐06	  
	  Jam2	   2.354175718	   5.75E-­‐36	  
	  Spata31d1b	   2.339751153	   0.000205062	  
	  Rasgrf2	   2.326602927	   8.39E-­‐09	  
	  Inpp5d	   2.325755919	   5.06E-­‐61	  
	  5830418P13Rik	   2.307600423	   1.86E-­‐07	  
	  Cml2	   2.307274096	   1.46E-­‐28	  
	  Diras2	   2.296614329	   4.81E-­‐08	  
	  Ltb4r1	   2.295954709	   6.31E-­‐10	  
	  Plxna4	   2.291587121	   0.001908596	  
	  Slc25a45	   2.284222179	   0.000112082	  
	  Olfml1	   2.277021117	   5.77E-­‐06	  
	  2410021H03Rik	   2.271917171	   2.44E-­‐06	  
	  Foxd1	   2.25236321	   0.000101835	  
	  C86695	   2.226168874	   9.60E-­‐05	  
	  Esrrb	   2.225846674	   2.90E-­‐19	  
	  Pdgfa	   2.22420142	   4.32E-­‐41	  
	  Cd80	   2.207447658	   9.65E-­‐14	  
	  Neb	   2.202727601	   3.34E-­‐24	  
	  Klhl6	   2.188473914	   3.37E-­‐05	  
	  Mmrn2	   2.182942899	   9.98E-­‐12	  
	  Gm10696	   2.182396623	   6.82E-­‐06	  
	  Ttn	   2.182200808	   3.88E-­‐12	  
	  Upk3b	   2.177271117	   0.010041369	  
	  Mylpf	   2.161639012	   4.62E-­‐50	  
	  Pou3f3	   2.161325668	   3.99E-­‐06	  
	  Tchh	   2.15292874	   3.62E-­‐15	  
	  Mir292b	   2.138296005	   0.016204244	  
	  Neat1	   2.133785513	   1.09E-­‐15	  
	  Abca8b	   2.129601389	   1.24E-­‐13	  
	  Ak7	   2.124054162	   6.62E-­‐06	  
	  9130227L01Rik	   2.109717762	   0.015842782	  
	  Arid5b	   2.109110749	   2.29E-­‐66	  
	  C130026I21Rik	   2.108896147	   0.018957603	  
	   119	  
	  Sva	   2.102609365	   0.01100749	  
	  Tfap2c	   2.096585037	   2.35E-­‐35	  
	  Hoxc13	   2.09511869	   7.29E-­‐07	  
	  Synpo2l	   2.089942864	   2.96E-­‐05	  
	  Tpo	   2.081591074	   0.000138276	  
	  Olfr815	   2.080304341	   2.46E-­‐05	  
	  Gm4858	   2.07629699	   1.16E-­‐17	  
	  BC064078	   2.073850861	   0.000165856	  
	  4930525G20Rik	   2.071789846	   0.008185063	  
	  Scn3b	   2.063165234	   9.75E-­‐14	  
	  Vmn2r1	   2.062746123	   0.004050919	  
	  Tfcp2l1	   2.047943092	   1.02E-­‐21	  
	  Tlx3	   2.045706989	   0.001429538	  
	  Nkx2-­‐9	   2.041335174	   1.23E-­‐11	  
	  Pik3ap1	   2.039072413	   1.09E-­‐05	  
	  Klf4	   2.038754173	   1.67E-­‐11	  
	  Prdm14	   2.035229667	   5.39E-­‐05	  
	  Megf11	   2.034920771	   9.39E-­‐12	  
	  Ctsw	   2.029207275	   0.000253257	  
	  Gm5039	   2.028008081	   1.60E-­‐39	  
	  Mapt	   2.02670327	   6.01E-­‐14	  
	  Calcoco2	   2.024959598	   7.75E-­‐17	  
	  Itln1	   2.024529979	   0.00032023	  
	  Phf11a	   2.023413218	   1.16E-­‐05	  
	  Igsf23	   2.020146167	   4.30E-­‐08	  
	  Dusp27	   2.017825458	   1.04E-­‐25	  
	  Zbtb7c	   2.013278725	   0.000755916	  
	  Iqcf1	   2.010747316	   0.015531641	  
	  Plaur	   2.007498925	   3.20E-­‐31	  
	  AU015836	   2.006988281	   2.75E-­‐22	  
	  Pdzd2	   2.005244071	   1.12E-­‐17	  
	  Txlnb	   2.004376675	   3.45E-­‐06	  
	  1700096K18Rik	   2.003765664	   0.01564669	  
	  Fbxo15	   2.001792999	   1.60E-­‐39	  
	  Tex19.1	   2.001465877	   6.89E-­‐59	  
	  Gm9926	   -­‐2.034847034	   0.013477627	  
	  Ldb2	   -­‐2.077879052	   2.42E-­‐09	  
	  Trim33	   -­‐2.098173819	   1.70E-­‐143	  
	  Megf10	   -­‐2.128969248	   0.016184187	  
	  Fhl2	   -­‐2.14284755	   0.000949023	  
	  Camk1g	   -­‐2.214747808	   0.000314614	  
 
 
